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INTRODUCTION 
 The experimental evaluation of INJI DRAVAGAM extract of Zingiber officinale 
and Carum copticum on wistar albino rats on both sex reveals the drug was evaluated for 
Anti-ulcer (peptic ulcer), Anti-inflammatory and Analgesic activities on gastric mucosa. 
 As per the Siddha literature “Yaakopu Vaithiya chinthamani 500” approved by 
concerned department HOD. 
 The wistar albino rats tried for Acute, Sub-acute and sub-chronic toxicity studies 
etc. 
 The extract of trial drug Inji Dravagam was prepared as per non shasthric 
preparation and approved by IAEC Ref no (KKCP/2015/28-10.08.2015) 
 The qualitative and quantitative analysis on Inji Dravagam was carried out in 
National Institute of Siddha and Captain Srinivasamurthi Research center for Ayurveda 
and Siddha drug Development in Arumbakkam, chennai. 
 The toxicity studies were carried out for acute, sub-acute toxicity studies at K.K 
college of pharmacy in Gerugampakkam and sub-chronic toxicity study was carried at 
National Institute of Siddha.  
 The studies reveals acute toxicity studies in rats indicated that Inji Dravagam was 
non-toxic and no behavioral changes were observed up to the dose level of 10ml/kg body 
weight. The oral route was selected for use because oral route is considered to be a 
proposed therapeutic route. 
  As per the OECD guidelines, WHO norms for AYUSH drug Inji 
Dravagam was analyzed and reported were tabulated.   
 The animal study reveals histopathological examination of organs of animals 
administered with highest dose showed no changes in the cellular architecture. This could 
be conformed no- observed-adverse-effect level (NOAEL) on acute, repeated 28days oral 
and 90 days oral toxicity studies. 
As per the studies the drug Inji Dravagam has no remarkable toxicities in the 
animal models and this drug may be tried further for clinical use. 
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2. AIM AND OBJECTIVES 
AIM 
 To evaluate the safety and pharmacological profile of the test drug “Inji 
Dravagam” in animal model. 
OBJECTIVES 
 Review of various information both (Siddha and modern) relevant to the study. 
 Preparation of the trial drug as per classical Siddha literature. 
 Analysis of the trial drug 
 
 Pytochemical analysis. 
 Chemical analysis to evaluate acid and basic radicals. 
 Gas Chromatography. 
 ICP-OES. 
 
 Toxicity study: 
 
 Acute oral toxicity study   (OECD - 423 Guideline) 
 28 days Repeated oral toxicity  (OECD - 407 Guideline) 
 90 days Repeated oral toxicity  (OECD - 408 Guideline) 
    
 Pharmacology activity in wistar albino rats and mice: 
 
 Anti ulcer activity  (Aspirin induced method) 
 Anti inflammatory activity (Cotton pellet induced granuloma method) 
 Analgesic activity  (EDDy’s Hot plate method) 
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3. MATERIALS AND METHODS 
STANDARD OPERATIVE PROCEDURE OF INJI DRAVAGAM 
Drug selection 
 In this research work, the Inji Dravagam
1 
herbal formulation has been selected to 
evaluate as a trial drug from Siddha literature Yaakopu Vaithiya Chinthamani-700. 
Ingredients 
1. Purified fresh Ginger juice  - (Zingiber officinale) 
2. Purified Omam   - (Carum copticum)               
Source of Collection 
 Fresh gingers were collected from Tambaram sanatorium, Chennai, Tamilnadu. 
Omam was procured from a well reputed country shop in Parrys, Chennai.  
Identification and Authentication of the drug 
 The Herbal drugs were Identified and authenticated by competent authority 
department of Gunapadam, National Institute of Siddha, Tambaraum sanatorium, Chennai. 
Purification of Ingredient 
Purification of Omam
2
 
 Omam was purified by soaked in limestone water for three hours and then it was 
fried. 
Purification of Inji
3
 
 Inji was purified by removing the outer layer of skin. 
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  ,Q;rp        Xkk; 
 (Zingiber officinale)           (Carum copticum)                    
                     
 
Method of drug preparation 
 Purified Fresh raw ginger is taken then smashed and squeezed to get the fresh 
juice. The fresh juice is collected in mud vessel. Along with the fresh juice, Omam is 
added and then subjected to the distillation process by vaaluka yanthram. Finally 
Dravagam was collected and stored. 
                               
 
 
 
The distillation process was done at Gunapadam practical lab of NIS. 
5 
 
     
                                                        INJI DRAVAGAM                          
Labelling 
   
Name of the preparation : Inji Dravagam 
Date of preparation  : 12/06/15 and 25/02/16 
Dose    : 5ml bd 
Adjuvant/Vehicle  : Water 
Indications   : Gunmam (Peptic ulcer) 
Date of expiry   : 1 year from the date of manufacture 
Therapeutic Administration of drug 
Form of medicine  - Liquid (Pale yellow)  
Route of administration - Oral 
Dose    - 5ml 
Vehicle   - Water 
Time of administration           -           Twice in a day 
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4. REVIEW OF LITERATURE 
4.1 GUNAPADAM REVIEW 
    ,Q;rp – Inji 
                 (Zingiber officinale) 
NtW ngaHfs;: my;yk;, Mh;j;jpufk;> Mj;jpufk;, ,yhf;nfhl;il, eWkUg;Gkjpy;. 
Botanical Name :    Zingiber officinale 
English name  :    Green ginger fresh root 
Family  :    Zingiberaceae 
gad;gLk; cWg;G:  fpoq;F 
Rit  : fhh;g;G  
jd;ik : ntg;gk;  
gphpT  : fhh;g;G 
nra;if:  
  mfl;Ltha;tfw;wp 
  grpj;jPj;J}z;b 
  ckpo;ePh;ngUf;fp 
  nrhpg;Gz;lhf;fp 
  ntg;gKz;lhf;fp 
  jbg;Gz;lhf;fp 
Fzk;:   
  ,Q;rpf; fpoq;Ff; fpUky; Iak; xf;fhsk;  
  tQ;rpf;FQ; rd;dpRuk; td;Ngj - tpQ;Rfpd;w 
  #iyaWk; thjk;Nghe; J}z;lhj jPgdkhk; 
  NtiyAWq; fz;zha; - tpsk;G.                (mfj;jpah; Fzthflk;) 
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nghUs;: 
  nts;Nshf;fhsk;> tsp#iy> nrhpahf; fopr;ry; ,it Nghk;. 
grpAz;lhFk;.  
tof;F : 
  ,Q;rpiag; ghypy; miuj;Jf; fow;rpasT 18kp.yp ghypy; fhiy 
khiy nfhLj;Jtu Fd;kk; ,Uky; kaf;fk; moy;tha;T jPUk;. grpcz;lhFk;.  
  ,Q;rp NjD}wy; nra;J nfhLf;f mfl;il gw;wpa tapw;W typ> 
tapw;W nghUky;> the;jp> Fly; Neha;fs; jPUk;.  
  nrhpahf; fopr;rYf;F ,Q;rpr; rhw;iw> njhg;Gisr; Rw;wpj; jltyhk;. 
  the;jp> Xf;fhsk;> ,itfSf;F ,Q;rp rhW> ntq;fha rhW> tiff;F 
xU Njhyh tPjk; vLj;J fye;J nfhLf;fyhk;4.  
,Q;rp NrUk; kUe;Jfs;: 
 ney;ypf;fha; Nyfpak;5 
 nrsghf;ar; Rz;b6 
 ,Q;rp ,urhadk;;7 
 ,Q;rp Fok;G8 
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    2. Xkk; 
       (Carum copticum) 
 
NtW ngah;fs;:  mrNkhjk;> jPg;gpak;. 
Botanical Name :  Carum copticum  
English Name :  The Bishops weed 
Family     :  Apiaceae 
gad;gLk; cWg;G:  tpij 
Rit  : fhh;g;G 
jd;ik : ntg;gk; 
gphpT  : fhh;g;G 
nra;if : 
  grpj;jPj;J}z;b 
  ,rptfw;wp 
  mfl;Ltha;tfw;wp 
  mOfyfw;wp 
  ntg;gKz;lhf;fp 
  cukhf;fp 
  ckpo;ePh;ngUf;fp 
Fzk;. 
  rPjRuq; fhrQ; nrhpahke; jk;nghUky;  
  Ngjpapiur; ry;fLg;G Nguhkk; -XjpUky; 
  gy;nyhLgy; %yk; gfkpitNeh nad;nrANkh 
  nrhy;nyhLNghk; Xknkdr; nrhy;. 
 
 
9 
 
nghUs;: 
  nrhpahke;jk;> nghUky;> fopr;ry;> Flypiur;ry; ,it Nghk;. 
tof;F: 
  Xkk;> Rf;F> rpj;jpu%y Nth;gl;il ,k;%d;Wk; Xhpil nghbj;J fye;j 
vilf;F Neh; fLf;fha; nghb fye;J nfhLf;f ke;jk; jPUk;. 
  Xkk;> kpsF tiff;F 34fpuhk; ,tw;iw ntJg;gp nty;yk; 34fpuhk; 
Nrh;j;jiuj;J> 10 ehs; nfhl;il ghf;fsT rhg;gplTk; tapw;Wf;fLg;G> nghUky;> 
fopr;ry; jPUk;. 
  Xkj;jPePh; 30-60kpyp nfhLf;f Cop> tapw;WnghUky;> tapw;Wtyp> 
nrhpahf;fopr;ry;> ke;jk;> ,itfis jPh;f;Fk;;. 
  Xkk;> ,e;Jg;G> MlhNjhilr;rhW> ,Q;rpurk;> gor;rhW> Gjpdhr;rhW 
,itfis ghtid nra;J nfhLf;f mrPuzk;; jPUk;. 
 
NrUk; kUe;Jfs;: 
 Kg;gpuz;il #uzk;9 
 rhKjur; #uzk;10 
 Fkl;bf;fha; Fok;G 
 madhjp tlfk ;11 
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4.2 BOTANICAL REVIEW 
    INJI – Zingiber officinale 
Botanical name - Zingiber officinale 
Family     - Zingiberaceae 
VERNACULAR NAME: 
  English :  Ginger 
  Hindi  : Adrakh 
   Tamil  : Inji  
PARTS USED: 
   Rhizome  
ORGANOLEPTIC CHARACTERS 
  Odour  : Aromatic  
  Taste  : Pungent, Hot, 
ACTION 
   Carminative 
  Stomachic 
  Stimulant 
   Digestive 
  Sialagogue 
  Rubefacient
12
 
CHEMICAL CONSTITUENTS 
Volatile oils 
   Gingerol, shogaol, zingiberene and zingiberol1-3
13 
11 
 
PHYTOCHEMICAL PROPERTY 
 α-curcumene , β-D- curcumene, α- bergamotene , β-phellandrene, calamene, α -
bisabolene, D-borneol and its acetate ,camphene, geranial,  hepatane, methylhepatone,  
glutamic acid, gingerone
14
. 
MEDICINAL USES: 
It is recommended during pregnancy and treating for morning sickness. 
It is aromatic and beneficial in dropsy, dyspepsia, digestive and stomachic. 
Ginger decotion is give for colic pain, tympanites and vomiting. 
Ginger is used in tooth-ache, gout, rheumatism of the jaws. 
Relaxed sore throat, hoarseness and loss of voice are benefited by chewing a piece 
of ginger so as to produce copious flow of saliva.  
Ginger possess anti oxidant property and may be added to edible oils and fats to 
protect them against oxidative rancidity
15
. 
SUPPORTIVE ARTICLES: 
Anti-ulcer activity: 
Indomethacin induced ulcer - The extract used were freshly prepared as a suspension in 
normal saline and administered per orally to the animals in 5 ml/kg doses. Erosions 
formed on the glandular portions of the stomach of rat models were counted and the ulcer 
index calculated as described by Main and Whittle, 1975. (Urushidani et al 1979). Ginger 
extract dose of 100 mg/kg showed 71% inhibition of ulcer, which was comparable to that 
of ranitidine, the anti-ulcer drug used, which had 78% inhibition
16
. 
Anti-Inflammatory activity: 
 Ginger has been shown to share pharmacological properties with non-steroidal 
anti-inflammatory drugs (NSAIDs) because it suppresses prostaglandin synthesis through 
the inhibition of cyclooxygenase-1 and cyclooxygenase-2. However, ginger can be 
distinguished from NSAIDs based on its ability to suppress leukotriene biosynthesis by 
inhibiting 5-lipoxygenase
17
. (Mahady G.B et al, 2003) 
 
Further related activities are Anti inflammatory, Analgesic, Antiemetic, 
Antiarthritic, Antioxidant
18
.                             
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   OMAM - Carum copticum 
 
BOTANICAL NAME - Carum copticum 
FAMILY                     -  Apiaceae 
VERNACULAR NAME: 
  English   :  The bishops weed 
  Hindi     :  Ajvayam 
  Sanskrit  :  yavani 
PART USED: 
  Seeds 
ORGANOLEPTIC CHARACTERS: 
  Taste  :  Bitter, Pungent 
  Nature  :  Hot 
  Division  :  Pungent  
ACTION: 
  Stomachic 
  Anti-spasmodic 
  Tonic 
  Anti- septic 
  Carminative 
  Aphrodisiac 
  Laxative
19
 
 
CHEMICAL CONSTITUENTS: 
  Carum copticum have different classes of chemical constituent such as 
Volatile oil, Minerals and Vitamin, Steroid and other constituents. 
13 
 
Volatile oil: 
  Thymol, para-cymene, gama-terpinene are main volatile oil constituent.  
Carvacrol, α- and β-pinene,  terpine  phenolic compounds is secondary constituent20. 
 Minerals and vitamins:  
  Minerals, Calcium, Phosphorous, Iron and Nicotinic acid
21
. 
 Steroid: 
  6-O-β-glucopyranosyloxythymol,  
Phytochemicals: 
   Fiber (11.9%), carbohydrates (38.6%), tannins, glycosides, moisture 
(8.9%), protein (15.4%), fat (18.1%), saponins, flavones
23
. 
MEDICINAL USES:  
  It is used for therapeutic effect including bloating, fatigue , diarrhoea , 
abdominal tumors, and respiratory distress. 
  It has benefits such as anti-fungal, antioxidant, anti parasitic, and 
hypolipidemic effect
24
. 
 
SUPPORTIVE ARTICLES:  
Indomethacin-induced gastric ulcer 
  Indomethacin was suspended in 1% carboxymethylcellulose in water (6 
mg/ml) and administered to the fasted rats in a dose of 30mg/kg (0.5 ml/100 g). Rats were 
treated with ajowan suspension(250 and 500 mg/kg, orally) 30 min before indomathacin. 
Control rats were treated similarly with an equivalent amount of vehicle (Bhargava et al., 
1973). The stomachs of the animals shows significant reduction of gastric ulceration was 
noted
25
. 
 Thymol also possesses anti-inflammatory, analgesic and local anesthetic 
effects. 
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5. PHARMACEUTICAL REVIEW 
 Dravagam or Theeneer is the distilled essence, which contains the volatile 
constituents of the drugs used in the preparation, in a medium of water and is equivalent to 
“ aqua” or water of the western pharmacopoeia. 
The term Dravagam or Theeneer  denotes the acceptable aromatic nature of the 
drug and indicates that it is in the Aquous state. 
Preparation 
The preparation of Dravagam or Theeneer involves the efficient distillation of 
water soaked coarse powders of the drugs. The volatile principles which are evolved 
admixture with water vapor from the still are condensed and taken. 
Equipment required 
    Bottle of large capacity of handle the distillate. 
    An assembly of apparatus as described below or modifications thereof for distillation 
Process of preparation 
 The drugs are crushed into a coarse powder and soaked in the prescribed quantity 
of water, for about a day or at least over night and then charged into the still, along with 
the water. 
The lid is tightly set in and around to prevent leakage of vapours. For the purpose 
of sealing a cloth ribbon with a paste of black gram is used. Heat is applied to the drug 
mixture and distillate is collected in bottles, and then the whole condensate from one 
charging is thoroughly mixed, because the portions that had condensed later would be a 
weaker in concentration. A continuous water current should be maintained in the 
condenser. 
Storage 
Dravagam or theeneer should be stored in air tight containers of glass. If kept open, 
the volatile active principles will be lost by evaporation. 
 Dravagam or Theeneer is administered along with an equal volume of water
26
. 
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6. ANALYTICAL STUDY OF THE INJI DRAVAGAM 
 
 Analytical study of the trial drug brings the validation to be used as a medicine by 
subjecting the trial drug to many analysis and determining its quality and effectiveness. 
Analytical study includes many studies such as its organoleptic charcterization, physical 
characteristic, phytochemical property and also to assess the active principles and 
elements present in the trial drug. Thus analytical study brings the efficacy and potency of 
the drug. 
As per AYUSH protocol for analytical study, the following parameters were evaluated. 
 Organoleptic character 
 Colour  
 Odour   
 Taste 
 Physicochemical analysis 
 Physical characterization 
 Chemical analysis 
 Primary acid and basic radicals 
 Phytochemical analysis 
 TLC and HPTLC 
 Elemental analysis 
 ICP-OES 
 Gas chromatography  
6.1 ORGANOLEPTIC CHARACTER 
 
Colour 
  The medicine was taken into watch glasses and placed against white back ground 
in white tube light. It was observed for its colour by naked eye. 
Odour 
 The medicine was smelled individually. The time interval among two smelling was 
kept 2 minutes to nullify the effect of previous smelling. 
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6.3. CHEMICAL ANALYSIS OF INJI DRAVAGAM 
The chemical analysis of INJI DRAVAGAM was carried out in Bio chemistry Lab, 
National institute of siddha. 
S.No EXPERIMENT OBSERVATION INFERENCE 
1.  Physical Appearance of extract Colourless 
 
 
2. Test for Silicate 
2ml of the sample was shaken well 
with distilled water. 
No Sparingly soluble 
 
 
 Absence of Silicate 
 
 
3. Action of Heat: 
 2ml of the sample was taken in a dry 
test tube and heated gently at first and 
then strong. 
 No White fumes 
evolved. 
No brown fumes 
evolved. 
 
Absence of 
Carbonate 
 Absence of Nitrate. 
 
 
 
4. Flame Test: 
2ml of the sample was made into a 
paste with con. HCl in a watch glass 
and introduced into non-luminous part 
of the Bunsen flame. 
 
No  bluish green 
flame  
 
 
Absence of copper 
 
 
5. Ash Test: 
A filter paper was soaked into a 
mixture of extract and dil. cobalt 
nitrate solution and introduced into the 
Bunsen flame and ignited. 
 
No Appearance of 
yellow colour flame 
 
 
 
 
 
flame  
 
 
 
flame 
 
Absence of sodium 
 
 
 
Preparation of Extract: 
 5ml of sample was taken in a 250ml clean beaker and added with 50ml of distilled 
water. Then it was boiled well for about 10 minutes. Then it was cooled and filtered in a 
100ml volumetric flask and made up to 100ml with distilled water. This preparation was 
used for the qualitative analysis of acidic/basic radicals and biochemical constituents in it. 
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S.N EXPERIMENT OBSERVATION INFERENCE 
 I. Test For Acid Radicals   
1. Test For Sulphate: 
2ml of the above prepared extract was 
taken in a test tube to this added 2ml 
of 4% dil ammonium oxalate solution 
No cloudy 
appearance 
Absence of Sulphate 
2. Test For Chloride: 
2ml of the above prepared extracts 
was added with 2ml of dil-HCl was 
added until the effervescence ceases 
off. 
Cloudy appearance 
present 
 
Presence of Chloride  
 
3. Test For Phosphate: 
2ml of the extract were treated with 
2ml of dil. Ammonium  molybdate 
solution and 2ml of con.HNo3 
No cloudy yellow 
appearance present  
Absence of Phosphate  
4. Test For Carbonate: 
2ml of the extract was treated with 
2mldil. magnesium sulphate solution 
No cloudy 
appearance 
 
Absence of  carbonate 
5. Test For Nitrate: 
1ml of the extract was heated with 
copper turning and concentrated 
H2So4 and viewed the test tube 
vertically down. 
 No Brown gas was 
evolved  
 
Absence of nitrate 
6. Test For Sulphide: 
1ml of the extract was treated with 
2ml of con. HCL 
 No rotten egg 
smelling gas was 
evolved 
Absence of sulphide 
7. Test For Fluoride & Oxalate: 
2ml of extract was added with 2ml of 
dil. Acetic acid and 2ml dil. calcium 
chloride solution and heated. 
 No cloudy 
appearance. 
Absence of fluoride 
and oxalate 
18 
 
 
8. 
Test For Nitrite: 
3drops of the extract was placed on a 
filter paper, on that-2 drops of dil. 
acetic acid and 2 drops of dil. 
Benzidine solution were added. 
No characteristic 
changes 
Absence of nitrite 
 
9. Test For Borate: 
2ml of the extract was made into paste 
by using dil-sulphuric acid and alcohol 
(95%) and introduced into the blue 
flame. 
 No Appearance of 
bluish green colour 
Absence of borate 
II. Test For Basic Radicals 
1. Test For Lead: 
2ml of the extract was added with 2ml 
of dil-potassium iodine solution. 
No Yellow 
precipitate was 
obtained 
 
Absence of lead 
2. Test For Copper: 
2ml of extract was made into paste 
with con. HCl in a watch glass and 
introduced into the non-luminuous 
part of the flame. 
No blue colour 
precipitate  
  Absence of    copper 
3. Test For Aluminium: 
To the 2ml of extract dil-sodium 
hydroxide was added in 5 drops. 
No characteristic 
changes  
 
 
 
 
 
 
 
characteristic 
changes chara 
Absence of    
Aluminium. 
 
 
 
 
 
 
 
 
 
 
 
4. Test For Iron: 
a. To the 2ml of extract add 2ml of 
dil-ammonium solution 
b. To the 2ml of extract 2ml  
thiocyanate solution and 2ml  of con 
HNo3 is added 
No Red colour 
appeared 
Absence of Iron 
5. Test For Zinc:  
To 2ml of the extract dil-sodium 
hydroxide solution was added in 5 
drops and dil-ammonium chloride is 
added.  
No White 
precipitate was 
formed 
 Absence of Zinc 
19 
 
6. Test For Calcium:  
2ml of the extract was added with 2ml 
of 4% dil-ammonium oxalate solution  
Cloudy appearance 
and white 
precipitate formed 
presence of calcium 
7. Test For Magnesium:  
To 2ml of extract dil-sodium 
hydroxide solution was added in drops 
to excess. 
No  White 
precipitate was 
obtained 
Absence  of 
magnesium 
8. Test For Ammonium: 
To 2ml of extract 1 ml of Nessler's 
reagent and excess of dil-sodium 
hydroxide solution are added. 
 Mild  Brown 
colour appeared 
Presence  of 
ammonium 
9. Test For Potassium: 
2ml of extract was treated of with 2ml 
of dil-sodium nitrite solution and then 
treated with 2ml of dil-cobalt nitrate in 
30% dil-glacial acetic acid. 
   
No Yellow 
precipitate was 
obtained 
 
 
Absence of potassium 
10. Test For Sodium: 
 2 pinches (50mg) of the extract is 
made into paste by using HCl and 
introduced into the blue flame of 
Bunsen burner. 
 
No yellow colour 
flame evolved. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Absence of sodium 
11. Test For Mercury:  
2ml of the extract was treated with 
2ml of dil-sodium hydroxide solution.  
 No Yellow 
precipitate was 
obtained 
 
Absence of Mercury 
12. Test For Arsenic:  
2ml of the extract was treated with 
2ml of dil-sodium hydroxide solution. 
 
No  Brownish red 
precipitate is 
obtained 
  
Absence of arsenic 
 
III. Miscellaneous 
1.
  
Test For Starch: 
2ml of extract was treated with weak 
dil-Iodine solution  
   
No Blue colour 
developed 
 
Absence of starch 
20 
 
2.
  
Test For Reducing Sugar: 
5ml of Benedict's qualitative solution 
was taken in a test tube and boil for 2 
minutes and added 10 drops of the 
extract and again boil it for 2 minutes. 
The colour changes are noted. 
  
No Brick red colour 
was developed  
 
Absence of  reducing 
sugar 
3. Test For The Alkaloids: 
a) 2ml of the extract was treated with 
2ml of dil-potassiumlodide solution. 
b)  2ml of the extract was treated with 
2ml of dil-picric acid. 
c)  2ml of the extract was treated with 
2ml of dil-phosphotungstic acid. 
 
 
Yellow colour 
developed 
 
 
Presence 
of Alkaloids 
4.
  
Test For Tannic Acid:  
2ml of extract was treated with 2ml of 
dil-ferric chloride solution  
 No Blue-black 
precipitate was 
obtained  
Absence of Tannic 
acid 
 
5.
  
Test For Unsaturated Compound: 
To the 2ml of extract 2ml of dil-
Potassium permanganate solution is 
added.  
 Potassium 
permanganate was 
not decolourised 
 Absence of 
unsaturated compound 
6.
  
Test For Amino Acid: 
2 drops of the extract was placed on a 
filter paper and dried well. 20ml of 
Burette reagent was added. 
No violet colour Absence of amino acid 
7. Test For Type of Compound: 
2ml of the extract was treated with 2 
ml of dil-ferric chloride solution.  
No green and red 
colour  
 
No Violet colour 
developed 
 
No Blue colour 
developed. 
Absence of 
quinolepinephrine 
pyrocatechoantipyrine
Aliphatic amino acid 
and meconic acid.  
Apomorphine 
salicylate and 
Resorcinol are absent  
Morphine, Phenol 
cresol and 
hydrouinone are 
present. 
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TLC/HPTLC finger print analysis: 
    
Thin layer chromatography (TLC) is a chromatographic technique used to separate 
the components of a mixture using a thin stationary phase supported by an inert backing. It 
may be performed on the analytical scale as a means of monitoring the progress of a 
reaction, or on the preparative scale to purify small amounts of a compound. 
 TLC/HPTLC is an analytical tool widely used because of its simplicity, relative 
low cost, high sensitivity, and speed of separation. TLC/HPTLC functions on the same 
principle as all chromatography: a compound will have different affinities for the mobile 
and stationary phases, and this affects the speed at which it migrates. The goal of 
TLC/HPTLC is to obtain well defined, well separated spots. 
Retention Factor 
 After a separation is complete, individual compounds appear as spots separated 
vertically. Each spot has a retention factor (Rf) which is equal to the distance migrated 
over the total distance covered by the solvent. The Rf formula is 
Rf  = distance traveled by sample /distance traveled by solvent 
 The Rf value can be used to identify compounds due to their uniqueness to each 
compound.  When comparing two different compounds under the same conditions. 
The compound with the larger Rf value is less polar because it does not stick to the 
stationary phase as long as the polar compound, which would have a lower Rf value
27 
 RESULTS: 
 The procedure recommended for the analysis of TLC and HPTLC analysis as per 
Wagner H and Bladt S, 1996 
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TLC and HPTLC Methodology: 
 Taken 15ml of the sample add 60ml Ethyl acetate keep it over night. Then Ethyl 
acetate layer was separated and dried over sodium sulphate anhydrous. Filtered and 
concentrated to 10ml at room temperature. 20µl, 25µl of the above solution were applied 
on Merck Aluminum plate pre-coated with silica gel 60F254 of 0.2mm thickness using 
ATS-IV. The plate was developed in Toluene: Ethyl acetate (8.2). The plate was dried and 
visualized in UV 254 and UV366nm and photographs were taken, the plate was scanned at 
254nm before dipping. Then the plate was dipped in vanillin-sulphuric acid and heated at 
105ºC till the colour of the spots appeared and photos were taken
28
. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HPTLC has been done at captain srinivasamurthir research institute for ayurveda and Siddha drug 
development 
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ELEMENTAL ANALYSIS 
D. INDUCTIVELY COUPLED PLASMA OPTICAL EMISSIOS 
SPECTROMETRY 
 The ICP- OES is a trace-level elemental analysis technique that uses the emission 
spectra of a sample to identify and quantify the elements present. The Experimental 
Procedure was done at SAIF, IIT Madras, Chennai-36. 
Introduction 
  The element composition of a sample is often an important part of the information 
needed to assess its properties. Hence there is a need for scientific instrumentation like 
ICP-OES which plays a pivotal role in the determination of these elements. ICP-OES is 
widely employed for the estimation of metals and metallolids at trace, minor and major 
concentration. 
Principle  
 In this technique, the high temperature plasma source atomizes the sample and 
excites the atoms resulting in emission of photons. The atoms of each element in the 
sample emit specific wavelength of light. The emission spectrum from the plasma is 
dispersed by an optical spectrometer, so that intension of the individual wavelength can be 
measured. The number of photos emitted is directly proportional to the concentration of 
the element.  The photos may be detected either sequentially or simultaneously. 
Quantitative analysis is achieved by measuring the intensity of these specific wave length     
and after performing the calibration using known standards. 
Identifying the presence of emission at the wavelength characteristic of the element 
of interest obtaining quantitative information i.e, how much of an element is in sample can 
be accomplished using plots of emission intensity versus concentration called calibration 
curves. 
Sample preparation – Microwave Digestion 
 Weight 0.25 g of test sample and transfer into a liner provided with instrument. 
 Slowly add 9ml of Nitric acid or sulphuric acid such that no piece of sample sticks 
on the slide. 
 Mix thoroughly and allow reacting for few minutes. 
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 Place the liner in the vessel jacket. 
 Close the screw cap hand- tight in clockwise direction. 
 Seal the vessel and placed in the rotor fixed in microwave. 
 Set temperature to 180°C for 5 minutes, hold at 180°C for least 10 minutes.                                                                                                                                                           
Allow the vessels to cool down to a vessel interior temperature below 60°C and to 
a vessel surface temperature (IR) below 50°C before removing the rotor. 
 The digested sample was made upto 100ml with Millipore water. 
 If visible insoluble particles exist, solution could be filtered through whatmann 
filter paper. 
 Transfer the digested solution into plastic containers and label them properly. 
 
 
 
 
 
 
 
 
 
 
ICP-OES has been done at SAIF,IITM, Chennai-96. 
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GAS CHROMOTOGRPHY : (GC) 
Gas chromatography is a chromatographic separation technique based on the 
difference in the distribution of species between two non- miscible phase in which the 
mobile phase is a carrier gas moving through or passing the stationary phase contained in a 
column. It is applicable to substances or their derivatives, which are volatilized under the 
temperatures employed. 
GC is based on mechanism of adsorption, mass distribution or size exclusion. 
METHOD 
    Equilibrate the column, the injector and the detector at the temperatures and the 
gas flow rates specified in the monograph until a stable baseline is achieved. Prepare the 
test solution ( S) and the reference solution (S) as prescribed. The solution must be free 
from solid particles. 
GC-MS SPECTROMETER 
 
 The JEOL GCMATE II GC-MS with Data system is a high resolution, double 
focusing instrument. Maximum resolution: 6000 Maximum calibrated mass: 1500 Daltons. 
Source options: Electron impact (EI); Chemical ionization (CI) .    
 
                                                                                                  
 
                          
 
 
 
GC-MS has been done at SAIF,IITM, Chennai-96. 
26 
 
Applications 
1. Structural elucidation of organic compounds. 
2. Mechanistic study of fragmentation process under mass spectrometric condition. 
3. Molar mass and structural analysis of small biomolecules. 
 
GC profile: 
 
 Instrument   name       :   JEOL GC MATE II 
 Front inet temp          : 220 degree c 
 Column                       :  HP 5 Ms 
 Carrier gas                  :   high pure helium  
 Flow rate                    : 1 ml /min  
 Oven temp                  :  50 to 250 @ 10 deg / min 
 Ion chamber tem         :  250 deg c 
 GC interface temp       :  250 deg c 
 Mass analyzer             :  quadrupole with double focusing mass analyzer, 
 Detector                      : Photon multiplier tube  
 Scam                           :  50 to 600 amu 70ev electron impact ionization  
 
 
 
 
 
 
 
 
 
 
 
GC-MS has been done at SAIF,IITM, Chennai-96. 
  
 
 
 
TOXICITY STUDIES 
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7. TOXICITY STUDIES 
ACUTE ORAL TOXICITY-EXPERIMENT PROCEDURE 
Acute toxicity study was carried out according to the OECD (Organization of 
Economic Co-operation and Development) guidelines 423. Healthy female rats, weighing 
100-150 gm, were selected and oral administration of the single doses of Inji Dravagam 
was done aseptically by suspending in 1ml water. 
Experimental animals: 
 Albino rats (wistar rats) of either sex, weighing (100-150 gm) were procured from 
animal housing facility, K.K college of pharmacy, Gerugambakkam, Chennai. All animals 
were placed in a polypro  C 
and relative humidity of 60-70 % in animal house. The animals were maintained in 
standard pellet diet and water ad libitum. They were acclimatized to laboratory condition 
for seven days before commencement of the experiment. 
 All the protocols and the experiments conducted in strict compliance according to 
ethical principles and guidelines provided by committee for the purpose of control and 
Supervision of Experiments on Animals (KKCP/2015/028). Animal experimentation 
protocols are approved by Institutional Animal Ethical Committee. 
I. Acute oral toxicity study: 
The Acute toxicity studies were performed in accordance with the OECD 423 
guidelines. Female wistar rats weighing100 -150gm were selected and divided into 3 
groups containing three animals in each group. The single dose of Inji Dravagam the 
starting from 1ml/kg upto 10ml/kg (1, 5, 10ml/kg) was administered orally. The drug 
treated animals were carefully observed individually for the toxicity signs and mortality.  
The visual observations included skin changes, morbidity, aggressiveness, 
sensitivity to sound and pain, as well as respiratory movements were recorded. They were 
deprived of food, but not water 12 h prior to the administration of the test substance. 
Finally, the number of survivors were noted after 24 h and these animals were then 
maintained for a further 14 days and observations made daily. The toxicological effect was 
assessed on the basis of mortality. 
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Test Substance : Inji Dravagam 
Animal Source  : Animal house of King Institute of Preventive Medicine 
Animals : Male and Female Wistar Albino Rats  
Age  : More than 8 weeks 
Acclimatization : Seven days prior to dosing. 
Veterinary examination : Prior to and at the end of the acclimatization period. 
Identification of 
animals 
: By cage number, animal number and individual marking on 
fur. 
Diet : Pelleted feed supplied by Godrej foods Pvt Ltd, Bangalore 
Water  : Potable water in polypropylene bottles ad libitum. 
Housing & 
Environment 
: The animals were housed in Polypropylene cages provided 
with bedding of husk. 
Housing temperature : Between 20 & 24°C,  
Relative humidity : Between 30% and 70%, 
Dark and light cycle  : Each of 12 hours. 
 
OBSERVATIONS:  
 Animals were observed individually after dosing at least once during the first 30 
minutes, periodically during the first 24 hours, with special attention given during the first 
4 hours and daily thereafter, for a total period of 14 days, except where they need to be 
removed from the study and humanely killed for animal welfare reasons or are found dead. 
It should be determined by the toxic reactions, time of onset and length of recovery period 
and may thus be extended when considered necessary. The times at which signs of toxicity 
appear and disappear are important, especially if there is a tendency for toxic signs to be 
delayed.  
All observations were systematically recorded with individual records being 
maintained for each animal. Observations include changes in skin and fur, eyes and 
mucous membranes, and also respiratory, circulatory, autonomic and central nervous 
systems and somato motor activity and behavior pattern. Attention was directed to 
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observations of tremors, convulsions, salivation, diarrhoea, lethargy, sleep and coma. The 
principles and criteria summarized in the Humane Endpoints Guidance Document taken 
into consideration. Animals found in a moribund condition and animals showing severe 
pain or enduring signs of severe distress was humanely killed.  
When animals are killed for humane reasons or found dead, the time of death 
should was recorded. From the maximum dose 1\5th or 1\10th of the dose was considered 
as therapeutic dose for further study
29
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Acute toxicity study has been done at K.K College of Pharmacy 
  
 
 
REPEATED DOSE 28 
DAYS ORAL TOXICITY   
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II.SUB ACUTE TOXICITY STUDIES of “ Inji Dravagam “ in  rat                       - 
(OECD – 407 guidelines) 
Sub-acute toxicity studies were carried out according to OECD 407 and rats were 
divided into 3 groups of 10 animals (5 male and 5 female). Inji Dravagam was 
administered to rats at the dose of 5ml /kg/day and 10ml/kg/day for 28 days. The animals 
were observed daily for gross behavioural changes and other sign of sub acute toxicity. 
The weight of the each rat was recorded on day 0 and weekly throughout the course of the 
study, food and water consumption per rat was calculated. At the end of 28 days they were 
fasted overnight, each animal were anaesthetized with diethyl ether and blood samples 
were collected from the retro-orbital plexus into two tubes: one with EDTA for immediate 
analysis of haematological parameters, the other without any anticoagulant and was 
centrifuged at 4000 rpm at 4 °C for 10 minutes to obtain the serum. Serum was stored at 
20 °C until analyzed for biochemical parameters. 
Test Substance : Inji Dravagam 
Animal Source  : Animal house of King Institute of Preventive Medicine 
Animals : Male and Female Wistar Albino Rats  
Age  : More than 8 weeks 
Acclimatization : Seven days prior to dosing. 
Veterinary examination : Prior to and at the end of the acclimatization period. 
Identification of 
animals 
: By cage number, animal number and individual marking on 
fur. 
Diet : Pelleted feed supplied by Godrej foods Pvt Ltd, Bangalore 
Water  : Potable water in polypropylene bottles ad libitum. 
Housing & 
Environment 
: The animals were housed in Polypropylene cages provided 
with bedding of husk. 
Housing temperature : Between 20 & 24°C,  
Relative humidity : Between 30% and 70%, 
Dark and light cycle  : Each of 12 hours. 
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Justification for Dose Selection: 
 The results of acute toxicity studies in rats indicated that Inji Dravagam was non 
toxic and no behavioral change was observed up to the dose level of 10ml/kg body weight. 
The oral route was selected for use because oral route is considered to be a proposed 
therapeutic route.  
 As per OECD guideline three dose level were selected for the study. They are low 
dose (X), mid dose (5X), high dose (10X). X is calculated by multiplying the therapeutic 
dose (10ml) body surface area of the rat (0.018) i.e X dose 0.9ml/kg, 5X dose is 5ml/kg, 
10Xdose 10ml/kg. 
Preparation and administration of dose:   
 Inji Dravagam two doses level 5ml/kg and 10ml/kg respectively were prepared. 
The test substance was freshly prepared every day for 28 days. The control animals were 
administered water 10ml/kg vehicle only. Administration was by oral (gavage), once daily 
for 28 consecutive days. 
METHODOLOGY 
Randomization, Numbering and Grouping of Animals: 
 Ten Rats (Five Male and Five Female) in each group randomly divided into three 
groups for dosing upto 28 days. Animal’s acclimatization period of 7 days to laboratory 
conditions prior to the initiation of treatment. Each animal was fur marked with picric 
acid. The females were nulliporous and non-pregnant. 
OBSERVATIONS: 
 Experimental animals were kept under observation throughout the course of study 
for the following: 
i)Body Weight: 
Weight of each rat was recorded on day 0 at +weekly intervals throughout the course 
of study and at termination to calculate relative organ weights. From the data, group mean 
body weights and percent body weight gain were calculated. (table -9) 
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ii) Food and water Consumption:  
The quantity of food consumed by groups consisting of ten animals for different 
doses was recorded at weekly interval. Food consumed per animal was calculated for 
control and the treated dose groups. (table -11) 
iii) Clinical signs:  
All animals were observed daily for clinical signs. The time of onset, intensity and 
duration of these symptoms, if any, were recorded. 
iv) Mortality:  
All animals were observed twice daily for mortality during entire course of study. 
v) Laboratory investigation: 
Following laboratory investigations were carried out on day 29 in animals fasted 
over-night. On 29th day, the animals were fasted for approximately 18 h, then anesthetized 
with ether and blood samples were collected from the retro-orbital plexus into two tubes: 
one with EDTA for immediate analysis of haematological parameters, the other without 
any anticoagulant and was centrifuged at 4000 rpm at 4 °C for 10 minutes to obtain the 
serum. Serum was stored at 20 °C until analyzed for biochemical parameters. 
Haematological Investigations:  
Blood samples of control and experimental rats was analyzed for hemoglobin 
content, total red blood corpuscles (RBC), white blood corpuscles (WBC) count, Mean 
corpuscular volume (MCV) and packed cell volume (PCV). From the estimated values of 
RBC count (millions/mm3) and PCV (volumes percent), mean corpuscular volume (MCV) 
was calculated.  
Biochemical Investigations:  
Serum and Urine was used for the estimation of biochemical parameters. Samples 
of control and experimental rats were analyzed for protein, bilirubin, urea, uric acid, 
creatinine, triglyceride, cholesterol and glucose levels by using standard methods. 
Activities of glutamate oxaloacetate transaminase/ Aspartate aminotransferase 
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(GOT/AST), glutamate pyruvate transaminase/ Alanine amino transferase (GPT/ALT) and 
alkaline phosphatase were estimated as per the colorimetric procedure.  
Necropsy: 
All the animals were sacrificed on day 29. Necropsy of all animals was carried out 
and the weights of the organs including liver, kidneys, adrenals, spleen, brain, heart, uterus 
and testes/ovaries were recorded. The relative organ weight of each animal was then 
calculated as follows;     
                                                       Absolute organ weight (g) 
Relative organ weight = ____________________________________________ ×100 
    Body weight of rats on sacrifice day (g) 
Histopathology:  
Histopathological investigation of the vital organs was done. The organ pieces (3-
5µm thick) of the highest dose level of 10ml /kg were preserved and were fixed in 10% 
formalin for 24 h and washed in running water for 24h. Samples were dehydrated in an 
auto technicon and then cleared in benzene to remove absolute alcohol.  Embedding was 
done by passing the cleared samples through three cups containing molten paraffin at 
50°C and then in a cubical block of paraffin made by the “L” moulds. It was followed by 
microtome and the slides were stained with Haematoxylin-eosin.   
The organs included heart, kidneys, liver ,spleen and pancreas of the animals were 
preserved they were subjected to histopathological examination. 
Statistical analysis:  
Findings such as clinical signs of intoxication, body weight changes, food 
consumption, haematology and blood chemistry were subjected to One-way Anova 
Followed by Dunnet’t’ test using a computer software programme30. (Graph Pad Prism 
5.0) 
 
 
Sub-Acute toxicity study has been done at K.K College of Pharmacy 
  
 
 
REPEATED DOSE 90 
DAYS ORAL TOXICITY  
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7.3 90-DAYS REPEATED DOSE ORAL TOXICITY STUDY OF 
INJI DRAVAGAM (OECD GUIDELINE - 408) 
Test Substance  : INJI DRAVAGAM 
Animal Source  : King Institute, Guindy, Chennai.   
Animals   : Wistar Albino Rats (Male -5, and Female-5) 
Age    : 6-8 weeks 
Body Weight    : 150-200gm. 
Acclimatization  : Seven days prior to dosing. 
Veterinary examination : Prior and at the end of the acclimatization period. 
Identification of animals : By cage number, animal number   and    individual   marking    
  by using Picric acid. 
 
Diet    : Pellet feed supplied by Sai meera foods Pvt Ltd,        
       Bangalore 
Water    : Aqua guard potable water in polypropylene bottles. 
Housing & Environment : The animals were housed in Polypropylene cages   
       provided with bedding of husk. 
Housing temperature : Between 22ºC +3ºC.  
Relative humidity  : Between 30% and 70%, 
Air changes    : 10 to 15 per hour  
Dark and light cycle   : 12:12 hours. 
Duration of the study : 90 Days. 
 
METHODOLOGY 
Randomization, Numbering and Grouping of Animals: 
90days Chronic toxicity study were carried out according to OECD 408 and were 
divided into 4 group. Each group of 6 animals (Male-3 and Female-3) totally 24 animals. 
Group I treated as a control and other three groups were treated with test drug (low dose, mid 
dose, high) dose for 90 days. Animals were allowed acclimatization period of 7 days to 
laboratory conditions prior to the initiation of treatment.  
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The principles of laboratory animal care were followed and the Institutional Animal 
Ethical Committee approved Number: NIS/IAEC-I/2016/03. Each animal was marked with 
picric acid. The females were nulliparous and non-pregnant. 
Justification for Dose Selection: 
         As per OECD guideline three dose levels were selected for the study. They were low 
dose (X), mid dose (5X), high dose (10X). X was calculated by multiplying the therapeutic 
dose (2000mg) and the body surface area of the rat (0.018). i.e X dose was 0.9ml/kg. 5X dose 
was 5ml/kg, 10Xdose was 10ml/kg. 
Preparation and Administration of Dose: 
 Inji Dravagam was suspended in water to obtain concentrations of 10ml/kg. It was 
administered to animals at the dose levels of X, 5X, 10X. The test substance suspensions 
were freshly prepared every two days once for 90 days. The control animals were 
administered vehicle only. The drug was administered orally by using oral gavage once daily 
for 90 consecutive days. 
OBSERVATIONS: 
Experimental animals were kept under observation throughout the course of 
study for the following: 
 Body Weight: 
 Weight of each rat was recorded on day 0, at weekly intervals throughout the course 
of study. 
 Clinical signs:  
All animals were observed daily for clinical signs. The time of onset, intensity and 
duration of these symptoms, if any, were recorded. 
 Mortality: 
All animals were observed twice daily for mortality during entire course of study. 
 Laboratory Investigations: 
 Following laboratory investigations were carried out on day 91 in animals 
fasted over-night. Blood samples were collected from orbital sinus using sodium 
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heparin (200IU/ml) for Bio chemistry and potassium EDTA (1.5 mg/ml) for 
Haematology as anticoagulant. Blood samples were centrifuged at 3000 r.p.m. for 10 
minutes. 
 Haematological Investigations: 
 Haematological parameters were determined using Haematology analyzer.  
 Biochemical Investigations:  
 Biochemical parameters were determined using auto-analyzer. 
 Histopathology:   
 Control and highest dose group animals will be initially subjected to histopathological 
investigations. If any abnormality found in the highest dose group than the low, then the 
mid dose group will also be examined. Organs will be collected from all animals and 
preserved in 10% buffered neutral formalin for 24 h and washed in running water for 24 
h.  The organ sliced 5 or 6µm sections and were dehydrated in an auto technic on and 
then cleared in benzene to remove absolute alcohol. Embedding was done by passing the 
cleared samples through three cups containing molten paraffin at 50°C and then in a 
cubical block of paraffin made by the “L” moulds. It was followed by microtome and the 
slides were stained with Haematoxylin-eosin. 
 Statistical analysis: 
 Findings such as clinical signs of intoxication, body weight changes, food 
consumption, haematology and blood chemistry were subjected to One-way ANOVA 
followed by dunnet’t’test using a computer software programme31 -(Graph Pad Prism5) 
 
 
 
 
 
 
 
 
Sub chronic toxicity study has been done at NIS. 
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PHARMACOLOGY STUDIES 
ANTIULCER ACTIVITY ON GASTRIC MUCOSA (Aspirin Induced Gastric Ulcers)  
Aim: 
To evaluate the antiulcer activity of Inji Dravagam by Aspirin Induced Gastric Ulcers. 
Selection of Experimental animals: 
 Healthy Wistar albino rats of either sex weighing (150-250 gms ) were used for this 
study. The animals were obtained from animal house, K.Kcollege of pharmacy, 
Gerugambakkam, Chennai. Animals were housed at a temperature of 24±2c and relative 
humidity of 30-70%. At 12:12 light, day cycle was followed. All the animals were allowed to 
free access to water and fed with standard commercial pellet. All the experimental procedures 
and protocols used in this study were reviewed by (IAEC) Institutional Animal Ethics 
Committee (KKCP/2015/028) of K.K college of Pharmacy and were in accordance with the 
guidelines of the IAEC. 
Aspirin Induced Gastric Ulcers 
Principle: 
Aspirin was a NSAID which inhibit the synthesis of prostaglandins. Prostaglandins 
protect the gastric mucosa by producing leukotrienes and bicarbonate ions. Aspirin also 
inhibit the gastric peroxidase and may increase mucosal hydrogen peroxide and hydroxyl ions 
level to cause oxidative mucosal damage. 
Procedure: 
Albino rats of either sex weighing between 150-250 gms were divided into five 
groups and each consisting of six rats. 
 
Group I :   Vehicle control (2ml/kg p.o.) 
Group II :   Negative control received only Aspirin (500mg/kg) 
Group III :   Standard drug Ranitidine   + Aspirin (500 mg/kg) 
Group IV :   Received Inji Dravagam 1ml/kg + Aspirin (500 mg/kg)  
Group V :   Received Inji Dravagam 2ml/kg + Aspirin (500 mg/kg) 
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 The animals were fasted for 24 hours. The test drug in varying concentration 
Based on the design of the experiment is administered orally  30 minute prior to aspirin at  
Dose of 500 mg/kg. 4 hours later the rats were sacrified by using anaesthetic ether and their  
Stomach were dissected and they were opened along the greater curvature for the 
determination of gastric lesions . Ulcer index was calculated by nothing the number of ulcers  
per animal and severity scored by observing the ulcers microscopically with the help of 10X  
lens. 
 
Evaluation of parameters: 
Effect of Free Acidity and Total Acidity: 
The free acidity and total acidity was determined based on the titre values. One ml of 
gastric juice was pipette into 100 ml of conical flask and titrates with 0.01N NaOH using 
topfers reagent as an indicator (It is Dimethyl –amino-azo-benzene with phenolphthalein and 
used for the detection and estimation of hydrochloric acid and total acidity in gastric fluids) 
titrate to end point, when the solution turns to orange colour, note the volume of NaOH which 
corresponds to free acidity. Titrate further till the solution regains its pink colour. Note the 
volume of NaOH which corresponds to the free acidity. Acidity (mEq/L/100g)can be 
expressed as 
                           Acidity= ×100  
 
 Ulcer index: 
  The ulcer index was calculated by taking the mean ulcer score of each groups. Then 
the mean ulcer score graph was plotted with groups on x-axis and ulcer index on y-axis. The 
histograms of different groups were then interpolated by comparing the ulcer index of groups  
Collection of Gastric Juice 
The stomach was excised carefully opened along the greater curvature and the gastric 
contents were removed.  The gastric contents were collected in plain tubes and centrifuged at 
3000 rpm for 5 min, the volume of the supernatant was expressed as ml /100 gm body 
weight. The mucosa was flushed with saline and observed for gastric lesions using a 
dissecting microscope, ulcer score was determined. 
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Ulcer Scoring 
 After sacrificing the rat, stomach was removed and opened along the greater 
curvature, and washed it slowly under running tap water.  Put it on the glass slide and observe 
under 10X magnification for ulcer.  Score the ulcers as below. 
 
0 =  normal coloured stomach 
0.5 =  red colouration 
1 =  spot ulcers 
1.5 =  haemorrhagic streaks 
2  =  Ulcers ≥ 3 but ≤ 5 
3 =  Ulcers >5 
Mean ulcer score for each animal is expressed as Ulcer Index. 
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ANTI- INFLAMMMATORY ACTIVITY OF INJI DRAVAGAM ON WISTAR 
ALBINO RATS (Cotton pellet granuloma method) 
 
AIM: 
To evaluate the anti - inflammatory activity of Inji Dravagam in Wistar albino rats by 
Cotton pellet granuloma method. 
 Selection of Experimental animals: 
The experimental protocol was submitted and approved by institutional Ethical 
Committee, (IAEC approval No: KKCP/2015/028). Wistar albino rats (150- 180 gm ) of 
approximate same age were employed in this investigation. The animals were obtained from 
animal house, K.K college of pharmacy, Gerugambakkam, Chennai. Animals were housed at 
a temperature of 24±2c and relative humidity of 30-70% at 12:12 light, day cycle was 
followed. All the animals were allowed to free access to water and fed with standard 
commercial pellet.  
 
Experimental Design for Cotton pellet granuloma model 
  
The animals were divided into four groups each group consists of 6 animals. 
 
Group-I :   Control - Vehicle control received distilled water (dose: 10 ml/kg). 
Group-II :   Standard drug - Animals treated with Dexamethasone (dose: 0.5 mg/kg). 
Group-III :  Animals treated with Inji Dravagam (1 ml/kg) 
Group-IV :  Animals treated with Inji Dravagam (2 ml/kg) 
 
Experimental procedure 
 Inflammation was induced by cotton pellet granuloma model. This method was 
carried out by using sterilized cotton pellet implantation method in rats. Under light ether 
anesthesia by using blunted forceps, subcutaneous tunnel was made and sterilized cotton 
pellets (10 ± 1 mg) were implanted in the axilla and groin region of the rat. After recovering 
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from anaesthesia, animals were treated orally with vehicle control (Distilled water 10 ml / 
kg), Dexamethasone 0.5 mg/kg, low dose (1ml/kg) and high dose (2ml/kg) of Inji Dravagam 
for consecutive 7 days, once per day. They were sacrificed on day 8th by cervical dislocation 
and the pellets were removed and immediately the wet weight was taken, freed from 
extraneous tissue and dried at 600C for 24 hrs. The percentage inhibition of wet weight and 
dry weight of the granuloma were calculated and compared. 
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ANALGESIC ACTIVITY OF INJI DRAVAGAM ON SWISS ALBINO MICE (Eddy’s 
Hot plate method)  
AIM: 
To evaluate the Analgesic activity of Inji Dravagam in Swiss albino mice by Eddy’s 
Hot plate method. 
 
 Selection of Experimental animals: 
  Healthy Swiss albino mice of either sex weighing (20-25gms) were used for this 
study. The animals were obtained from animal house, k.k college of pharmacy, 
gerugambakkam, Chennai. Animals were housed at a temperature of 24±2c and relative 
humidity of 30-70%. At 12:12 light, day cycle was followed. All the animals were allowed to 
free access to water and fed with standard commercial pellet. All the experimental procedures 
and protocols used in this study were reviewed by (IAEC) Institutional Animal Ethics 
Committee (IAEC approval No: KKCP/2015/028) of K.K college of Pharmacy and were in 
accordance with the guidelines of the IAEC. 
Evaluation of Analgesic activity 
  Pain is the part of a defensive reaction against dysfunction of an organ or imbalance 
in its functions against potentially dangerous stimulus. The ascending pathway of pain 
includes the contralateral spinothalamic tract, lateral pons, mid brain to thalamus and 
ultimately through the somatosensory cortex of the brain that determines the locations, 
intensity and depth of pain 
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Eddy’s Hot plate method: 
Principle: 
 Painful reactions can be produced in experimental animals by applying noxious 
stimuli such as thermal – using radiant heat as a source of pain, chemical – using irritants 
such as acetic acid and bradykinin and physical pressure – using tail compression.  
The hot plate test is a test of the pain response in animals. It is used in basic pain research and 
in testing the effectiveness of analgesics by observing the reaction to pain caused by heat. 
 They used a behavioral model of nociception where behaviors such as jumping and hind 
paw-licking are elicited following a noxious thermal stimulus. Licking is a rapid response to 
painful thermal stimuli that is a direct indicator of nociceptive threshold. Jumping represents 
a more elaborated response, with a latency and encompasses an emotional component of 
escaping. 
Animals 
Mice 20-25 g were grouped in three groups, six animals in each group. 
Grouping: 
Group I  : Control - distilled water (10ml/kg, p.o.),   
Group II  : Standard drug - Pentazocine (5mg/kg, p.o.)  
Group III :          Received   Inji Dravagam ID (1ml/kg) 
Group IV : Received  Inji Dravagam ID (2ml/kg) 
Equipment: 
 Eddy’s Hot plate 
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Procedure: 
 Animals were weighed and placed on the hot plate. Temperature of the hot plate was 
maintained at 55±  C. Jumping response was seen. The time period (latency period), from 
when the animals were placed and until the responses occurred, were recorded using a 
stopwatch. To avoid tissue damage of the animals 10 seconds was kept as a cut off time.  The 
time obtained was considered the basal / normal reaction time in all the untreated groups of 
animals. Increase in the basal reaction time was the index of analgesia. All the animals were 
screened initially at least three times in this way and the animals showing a large range of 
variation in the basal reaction time were excluded from the study. A final reading of the basal 
reaction time was recorded for the included animals. After selecting the animals, the drugs 
were administered to all the groups at the stipulated doses. The reaction times of the animals 
were then noted at  0, 30 , 60 ,90 ,120 and 150 mins  interval after drug administration. 
Statistical analysis 
 Results were expressed as mean ± SEM and analyzed using Graph Pad Prism 
software. One way analysis of variance (ANOVA) test was applied. P value less than 0.05 
(P<0.05) was considered as statistically significant. 
 
 
 
 
 
  
 
 
 
RESULTS 
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RESULTS 
 
  In My research, studies like Organoleptic characters, physical characters, chemical 
analysis, phytochemical analysis, ICP-OES, Gas chromatography, Toxicity and 
pharmacological studies have been carried to know the potency and efficacy of the trial 
drug Inji Dravagam. 
  Botanical aspect explains the active principle and medicinal uses of the plants. 
  Gunapadam review brings the effectiveness of the drug in treating gunmam 
(peptic ulcer) 
  The pharmacological review explains about the Evaluation of Anti-ulcer, Anti-
inflammatory and analgesic activity. 
 
STANDARDIZATION OF THE TEST DRUG 
 Standardization of the drug is more essential to derive the efficacy, potency of the 
drug by analysing it by various studies. Following are the results of physicochemical and 
Phytochemical analysis, and estimation of basic and acidic radicals have been done and 
tabulated. 
 Toxicological results of the drug and pharmacological activity of the drug were 
derived. Its result has been tabulated and interpretation was made below. Thus it is to give 
a complete justification to bring the effectiveness of the trial drug Inji Dravagam. 
 
6.1 ORGANOLEPTIC CHARACTER 
Table 1: Organoleptic character of Inji Dravagam 
 
 
 
 
 
 
 
S. No Parameters Results 
 
1. Colour Pale yellow 
2. Odour Aromatic odour 
3. Taste Pungent 
4. State of matter Liquid 
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6.2 PHYSICAL CHARACTER 
Table 2: physical character of Inji Dravagam 
 
 
 
 
 
 
 
6.3 CHEMICAL ANALYSIS 
Table 3: Results of Acid radicals studies of Inji Dravagam 
S.NO Parameter 
 
Observation Result 
1 Test for Sulphate - Negative 
2 Test for Chloride Cloudy appearance 
present 
Positive 
3 Test For Phosphate - Negative 
4 Test For Carbonate - Negative 
5 Test For Nitrate - Negative 
6 Test for Sulphide - Negative 
7 Test For Fluoride &oxalate - Negative 
8 Test For Nitrite - Negative 
9 Test For Borax - Negative 
Interpretation 
The acidic radicals test shows the presence of Chloride 
S.No. Parameters Result 
     1 PH 5.02 
     2 Specific Gravity 0.9981 
     3 Volatile matter Negligible 
     4 TLC Separate 3 Nos of sheets were 
attached 
     5 HPTLC 
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Table 4: Results of basic radicals studies of Inji Dravagam 
S.NO Parameter Observation Result 
1 Test for Lead  
- 
Negative 
2 Test for Copper 
 
- Negative 
3 Test For Aluminium 
. 
 
- 
Negative 
4 Test For Iron 
. 
- Negative 
5 Test For Zinc  
- 
Negative 
6 Test for Calcium Cloudy appearance and 
white precipitate 
obtained 
 
 
Positive 
7 Test For Magnesium 
 
 
- 
Negative 
8 Test For Ammonium 
 
Mild brown colour 
appears. 
 
Positive 
 
9 Test For Potassium 
 
- Negative 
10 Test For Sodium 
 
 
- 
 
Negative 
11 Test For Mercury 
 
 
- 
 
Negative 
12 Test For Arsenic 
 
 
- 
 
 Negative 
 
 
Interpretation 
The basic radical test shows the presence of Ammonium, calcium and absence of heavy 
metals such as lead, arsenic and mercury. 
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6.4 TLC and HPTLC analysis of Inji Dravagam 
 The procedure recommended for the analysis of TLC and HPTLC analysis as per 
Wagner H and Bladt S, 1996 
Table: 5 TLC  and HPTLC analysis 
S.No 254nm 366nm Dipped in Vanillin-
Sulphuric Acid 
Colour Rf Colour Rf Colour Rf 
    1 Green 0.56 Blue 3.0 Grey 0.04 
    2 Green 0.84 Blue 6.8 Grey 0.1 
    3 Green 099   Grey 0.53 
    4 Green    Grey 0.89 
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TLC PHOTODOCUMENTATION OF DTL SAMPLE 1510357 
 
        UV254nm        UV366nm                       DERIVATISEDM WITH VANILLIN 
         SULPHURIC ACID 
 
Track 1 -20 µl , Track -2 -25 µl 
SOLVENT SYSTEM : TOLUENE : ETHYL ACETATE (8:2) 
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HPTLC FINGERPRINT PROFILE OF DTL SAMPLE 1510357 AT 254 nm at 20µl 
 
 
Track 3-ID DTL 10 
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HPTLC FINGERPRINT PROFILE OF DTL SAMPLE 1510357 AT 254 nm at 25µl 
 
Track 4 ID DTL-10 
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6.5 ELEMENTAL ANALYSIS  
Table :6 ICP-OES study results of Inji Dravagam 
 
S.NO 
 
Elements  
 
Wavelength in nm 
 
Inji  Dravagam mg/L 
 
    1. Arsenic  As 188.979      BDL 
    2. Calcium Ca 315.807      12.760mg/L 
    3. Cadmium Cd 228.802      BDL 
    4. Copper Cu 327.393      BDL 
    5.  Iron  Fe 238.204      08.346mg/L  
    6. Mercury  Hg 253.653      BDL 
    7. Potassium  K   766.491      23.821mg/L 
    8. Magnesium  Mg 285.213      11.153mg/L 
    9. Nickel  Ni  231.604      BDL 
    10. Phosphorus  P    213.617       19.341 
    11. Lead  Pb  220.353 
 
     BDL 
    12. Zinc Zn 206.200      01.258mg/L 
 
 
*  BDL – Below Detection Limit  
The results Shows the quantitative analysis of the elements present in Inji Dravagam . The 
heavy metals were found to be within normal limits. The presence of other elements shows 
the therapeutic value of Inji Dravagam. Hence the drug Inji Dravagam is considered as a 
safe drug. 
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6.6 Gas chromatography of Inji Dravagam 
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Interpretation: 
 Through GC-MS analysis can found the name molecular weight and structure of 
the test drug Inji Dravagam. 
 This image (table: 7) shows the characteristic gas chromatogram of Inji Dravagam. 
In this sample, there are 6 compound were identified, they are the following, 
(1) Furan,2-(2-ethoxy-3,4-dimethyl-2-cyclohexo-1-cylidene)methyl) 
(2) 5 Otadecenal 
(3) Ethyl 9-hexadecenoate 
(4) Pentadecandoic acid, methyl ester 
(5) 9-octadecenoic acid(Z),methyl ester 
(6) Heptadecanoic acid, 16, methyl, methyl ester 
 
Table: 7 Compounds identified in the trial drug Inji Dravagam 
 
S.NO Rt Name of the compound Molecular 
formula 
Molecular 
weight 
1 9.19 Furan,2(2-ethoxy-3,4-
dimethyl-2-cyclohexo-1-
cylidene 
C15 H20 O2   
 
232.0748 
 
2 10.36 5 Otadecenal C18 H34 O 252.2545 
3 11.18 Ethyl 9-hexadecenate C18 H34 O2 281.1372 
4 11.32 Pentadecanoic acid, methyl 
ester 
C16 H32 O2 239.1132 
5 12.49 9-Octadecenoic[Z] methyl 
ester] 
C19 H36 O2 296.1717 
6 12.66 Heptadecanoic acid, 16-
methyl- methyl ester 
C19 H38 O2 298.1546 
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TOXICOLOGY STUDY ON INJI DRAVAGAM 
7.1 Acute oral toxicity study of Inji dravagam 
Table 8: Dose finding experiment and its behavioural Signs of Toxicity in wistar albino rats  
No Dose 
ml/kg 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 
1 1 + - - - - + - - - - - - - - - - - - - - 
2 5 + - - - - + - - - - - - - - - - - - - - 
3 10 + - - - - + - - - - - - - - - - - - - - 
 
1.Alertness 2.Aggressiveness 3.Pilo erection 4.Grooming 5.Gripping 6.Touch Response 
7.Decreased Motor activity 8.Tremors 9.Convulsions 10.Muscle Spasm 11.catatonia 
12.Muscle relaxant 13.Hypnosis 14.Analgesia 15.Lacrimation 16.Exophthalmos 
17.Diarrhoea 18. Writhing 19.Respiration 20.Mortality 
+ Presence of Activity 
-Absence of Activity 
 All the data were summarized in the form of table (7) revealed no abnormal signs 
and behavioral changes in rats at the dose of 1, 5, 10, ml/kg body weight administered 
orally. 
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Table: 9 Body weight (g) of albino rats exposed to Inji Dravagam for 28 days  
 
Dose 
(mg/kg/day) 
 Days    
1 7 14 21 28 
Control 111.20±3.27 112.33±1.51 112.33±2.34 112.66±1.51 114.00±1.41 
Mid dose 112.33±1.51 113.16±0.98 115.08±0.86 115.16±0.75 116.66±0.82 
High dose 112.66±2.07 113.33±2.07 114.50±1.38 115.50±0.84 116.82±1.02 
 
Values are mean of a 10 animals ± S.E.M (Dunnet’s test) *p<0.05;**p<0.01.N=10 
 
Table: 10 Water (ml/day) intake of albino rats exposed to Inji Dravagam for 28 days 
 Dose(mg/kg/day)                                Days(ml/rat) 
1 7 14 21 28 
Control 35.12±0.75 35.5±0.55 36.0±0.63 37.0±0.89 35.5±2.17 
Mid dose  38.0±1.41 40.16±1.28 40.5±0.84 45.0±1.10 44.66±3.27 
High dose 41.0±1.10 42.66±1.03 44.33±1.51 44.0±2.83 46.0±2.83 
 
Values are mean of a 10 animals ± S.E.M (Dunnet’s test) *p<0.05;**p<0.01.N=10 
Table: 11 Food (g/day) intake of albino rats exposed to Inji Dravagam for 28 days 
 Dose 
(mg/kg/day) 
                              Days (gms/rats) 
1 7 14 21 28 
Control 37.46±0.78 36.48±1.63 41.35±0.91 41.28±0.99 42.65±2.92 
Mid dose 40.23±0.23 42.2±0.24 42.86±0.90 42.91±1.69 43.73±1.16 
High dose 41.38±0.58 41.96±0.40 43.11±0.97 43.53±1.02 44.7±1.60 
 
Values are mean of a 10 animals ± S.E.M (Dunnet’s test)* p<0.05;**p<0.01.N=10 
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Table: 12Hematological parameters after 28days treatment with Inji Dravagam  
in rats 
 
Parameters Control Mid dose High dose 
Red blood cell(mm
3
) 7.15±0.15 7.66±0.28 7.94±0.38 
HB(%) 14.23±0.21 14.98±0.28 15.13±0.21 
Leukocyte (x10
6
/ml) 10146±51.49 10179±22.10 10269±95.32 
Platelets/UL 1418±8.40 1281±33.10 1271±37.08 
MCV(gl) 51.57±0.98 54.42±0.63 54.45±2.19 
 PCV 35.02±0.04 35.62±0.12 35.60±0.10 
 
Values are mean of a 10 animals ± S.E.M (Dunnet’s test)* p<0.05 ;**p<0.01.N=10 
 
 
 
The mean value of  T.RBC of control and treated groups of wistar albino rats exposed to 
Inji Dravagam  in Repeated Oral 28 Days Toxic study. 
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The mean value of HB of control and treated groups of wistar albino rats exposed to  
Inji Dravagam in Repeated Oral 28 Days Toxic study. 
 
 
 
The mean value of Leucocytes of control and treated groups of wistar albino rats  
exposed to Inji Dravagam  in Repeated Oral 28 Days Toxic study. 
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The mean value of Platelets of control and treated groups of wistar albino rats exposed to 
Inji Dravagam  in Repeated Oral 28 Days Toxic study. 
 
 
The mean value of MCV of control and treated groups of wistar albino rats exposed to Inji 
Dravagam  in Repeated Oral 28 Days Toxic study. 
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The mean value of PCV of control and treated groups of wistar albino rats exposed to Inji 
Dravagam in Repeated Oral 28 Days Toxic study. 
 
Table 13:Effect of treatment with Inji Dravagam on biochemical parameters: 
LFT 
Dose(mg/kg) Control Mid dose  High dose 
Total Bilirubin (mg/dl) 0.2011±0.04 0.214±0.01 0.216±0.01 
Bilirubin direct(mg/dl) 0.1±0.02 0.1±0.02 0.1±0.04 
Bilirubin indirect(mg/dl) 0.1±00 0.1±00 0.1±00 
ALP(U/L) 377.6±40.27 364.00±30.35 355.66±4.63 
SGOT(U/L) 162.50±2.17 156.33±1.51 152.00±1.79 
SGPT(U/L) 39.90±1.01 40.97±0.97 44.20±0.61 
Total protein(g/dl) 10.70±0.55 9.36±0.21 9.18±0.04 
Albumin(g/dl) 3.06±0.03 3.06±0.03 3.07±0.04 
Globulin(g/dl) 6.06±0.05 5.79±0.09 5.27±0.05 
 
Values are mean of a 10 animals ± S.E.M (Dunnet’s test)* p<0.05;**p<0.01.N=10 
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The mean value of T. Bilirubin, Bilirubin direct and Bilirubin indirect of control and treated 
groups of wistar albino rats exposed to Inji Dravagam in Repeated Oral 28 Days Toxic study 
 
 
The mean value of ALP, SGOT and SGPT of control and treated groups of wistar albino rats 
exposed to Inji Dravagam in Repeated Oral 28 Days Toxic study 
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The mean value of Total protein, Albumin and Globulin of control and treated groups of 
wistar albino rats exposed to Inji Dravagam in Repeated Oral 28 DaysToxic study 
 
 
Table :14 Effect of Inji Dravagam on Renal function test 
Dose (mg/kg) Control Mid dose High dose 
Urea(mg/dl) 53.85±1.39 51.63±0.95 52.36±0.27 
Creatinine(mg/dl) 0.72±0.01 0.74±0.02 0.74±0.04 
Uric acid(mg/dl) 1.4±0.02 1.4±0.02 1.6±0.04 
Na m.mol 130.78±0.72 132.01±0.63 134.53±1.49 
K m.mol 18.12±0.07 18.28±0.03 19.23±0.17 
Clm.mol 97.57±0.80 99.26±0.23 99.33±1.16 
 
Values are mean of a 10 animals ± S.E.M (Dunnet’s test) *p<0.05;**p<0.01.N=10 
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Table 15: Lipid Profile 
Parameters Control  Mid dose  High dose  
Total cholesterol (mg/kg) 35.59±0.50 34.14±0.91 34.08±.0.81 
HDL(mg/dl) 12.26±0.16 12.28±0.12 12.24±0.12 
LDL(mg/dl) 37.90±1.36 39.26±0.89 38.73±1.47 
VLDL (mg/dl) 15.85±0.09 15.81±0.11 15.48±1.25 
Triglycerides(mg/dl) 79.44±0.01 77.34±2.16 77.89 ±2.29 
TC/HDL ratio (g/dl) 2.46±0.12 3.42±1.23 3.20±0.12 
Blood glucose (mg/dl) 124.03±0.21 124.17±0.30 124.03±0.11 
 
Values are mean of a 10 animals ± S.E.M (Dunnet’s test) *p<0.05;**p<0.01.N=10 
 
 
 
The mean value of total cholesterol, triglycerides, HDL, LDL, VLDL, of control and treated 
groups of wistar albino rats exposed to Inji Dravagam in Repeated Oral 28 Day Toxic study 
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Table 16: Urine Analysis of 28 Days Repeated oral toxicity study of Inji Dravagam in 
wistar albino rats 
 
 
 
 
 
 
 
 
 
 
 Values are mean of a 10 animals ± S.E.M (Dunnet’s test)* p<0.05;**p<0.01.N=10 
Table 17: Effect of oral administration of a Inji Dravagam on organ weight 
Dose (mg/kg) Control Mid dose High dose 
Liver(g) 4.44±0.12 4.53±0.19 4.58±0.05 
Heart (g) 0.39±0.04 0.39±0.03 0.39±0.02 
Lung(g) 1.30±0.24 1.30±0.68 1.30±0.88 
Spleen (g) 0.48±0.16 0.50±0.18 0.52±0.22 
Ovary (g) 1.48±0.04 1.50±0. 1.52±0.04 
Testes(g) 1.20±0.13 1.22±0.22 1.22±0.28 
Brain(g) 1.36±0.22 1.38±0.24 1.40±0.26 
Kidney(g) 0.60±0.04 0.62±0.04 0.64±0.04 
Stomach(g) 1.35±0.03 1.38±0.02 1.38±0.02 
 
Values are mean of a 10 animals ± S.E.M (Dunnet’s test) *p<0.05;**p<0.01.N=10 
Parameters Control Mid dose High dose 
Transparency Clear Slightly turbid Slightly turbid 
Specific gravity 1.010 1.010 1.010 
PH >7.2 >7.2 >7.4 
Protein Nil Nil Nil 
Glucose Nil Nil Nil 
Bilirubin -ve -ve -ve 
Ketones -ve -ve -ve 
Blood  Absent Absent Absent 
Urobilinogen Normal Normal Normal 
Pus cells 0-cells/HPF 0-cells/HPF 1-cells/HPF 
RBC Nil Nil 1-cells/HPF 
Epithelial cells Nil 1-cells/HPF Nil 
Crystals Nil Nil Nil 
Casts Nil Nil Nil 
Others Bacteria seen Bacteria seen Bacteria seen 
Colour yellow Yellow Yellow 
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HISTOPATHOLOGICAL STUDIES OF VARIOUS ORGANS AFTER THE 28 DAYS 
REPEATED DOSE ORALTOXICITY STUDY OF INJI DRAVAGAM IN WISTAR 
ALBINO RATS                                                  
Heart                                          Kidney 
                    
 Control               Control  
          
     
Mild dose                        Mild dose                   
                   
 High dose                High dose 
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HISTOPATHOLOGICAL STUDIES OF VARIOUS ORGANS AFTER THE 28 DAYS 
REPEATED DOSE ORALTOXICITY STUDY OF INJI DRAVAGAM IN WISTAR 
ALBINO RATS 
Liver                 Stomach: 
                  
Control                Control 
           
 Mild dose                           Mild dose   
      
High dose                High dose 
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HISTOPATHOLOGICAL STUDIES OF VARIOUS ORGANS AFTER THE 28 DAYS 
REPEATED DOSE ORALTOXICITY STUDY OF INJI DRAVAGAM IN WISTAR 
ALBINO RATS 
 
Spleen 
 
 
 
 
 
   
Control             Mild dose 
 
      
 
 
 
 
 
High dose 
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Interpretation: 
Heart: 
 Section of heart from control animal showed normal muscle fibers with acidophilic 
cytoplasm and centrally located nuclei. 
 In treated group showed normal muscle fibers with acidophilic cytoplasm and 
centrally located nuclei with normal structure. 
Kidney: 
 Section of kidney from control animals showed normal size of glomeruli with 
normal tubules. 
 Kidney of treated animals showed normal glomeruli and there is no necrosis of 
tubular epithelium in the kidney. 
Liver: 
 Section of liver from control animals shows No degeneration of hepatocytes, 
focalsteatosis, and congestion of central vein and inflammation of portal tract. 
 Liver of treated groups showed No degeneration of hepatocytes, focalsteatosis, no 
congestion of central vein and inflammation of portal tract  
Spleen:  
 
 Section of spleen from control animal shows normal granular hemosiderin pigment 
predominantly within macrophages in the red pulp. 
 Treated animals showed normal granular hemosiderin pigment predominantly 
within macrophages in the red pulp with normal structure. 
Stomach: 
 
 Section of stomach from control animals shows gastric mucosa lined by tall 
columnar cell with no abnormality. 
 Stomach of treated group animals shows gastric mucosa lined by tall columnar cell 
no abnormal changes. 
Heart, liver, kidney, and stomach showed no changes in the cellular architecture in 
treated groups. From the histopathological study no related changes in vital organs 
are observed in treated groups. 
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PRECLINICAL TOXICITY RESULTS OF INJI DRAVGAM 
Interpretation of Sub-acute toxicity of Inji dravagam 
            All animals from control and all the treated dose groups survived throughout the 
dosing period of 28 days for sub acute toxicity study. There was no significant change in 
the body weight for the control and treatment group throughout the dosing period of 28 
days. 
Intrepratation of hematological investigation  
The results of haematological investigations conducted on day 29
th
 day revealed no 
significant changes in the haematological values when compared with those of respective 
controls. This gave clear justification that bone marrow and spleen were not influenced by 
Inji dravagam. 
Intrepratation of Biochemical investigation 
Results of Biochemical investigations conducted on days 29 and recorded in 
revealed the no significant changes in the values of different parameters studied when 
compared with those of respective controls; Urea, SGOT,SGPT, Bilirubin were within the 
limits. 
Intrepretation of histopathology: 
    The vital organs such as liver, heart, kidneys, stomach and brain were removed from the 
test groups at the end of the study and carefully observed macroscopically to find any 
observable gross lesions compared with the control group and did not reveal any abnormal 
macroscopic changes. Cross pathological investigation was carried out and histopathology 
of vital organ reveled normal histological appearance when compared with the control. 
              Organ weights of treated animals with respective control animals on day 29 was 
found to be comparable with respective control group. Gross pathological examination of 
animals  did not reveal any abnormalities. Histopathology examination did not reveal any 
abnormal macroscopic changes. 
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7.3CHRONIC TOXICITY STUDY:  
Table:18 Haematological parameters of Wistar albino rats group exposed to Inji 
Dravagam for 90 days 
 
 
 
 
 
 
 
 
N.S- Not Significant, **(p > 0.01), *(p >0.05), n = 10 values are mean ± S.D (One way    ANOVA 
followed by Dunnett’s test ) 
 
The mean value of RBC and HB control and treated groups of wistar albino rats exposed to 
Inji Dravagam in Repeated Oral 90 Days Toxicity study. 
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HB
Parameter Control  1ml/kg 5ml/kg 10ml/kg 
RBC (mm3) 7.00±23 7.38±46 7.017±30 7.133±33 
 
PLATELET  
 
3.33±42 3.717±22 3.63±15 3. 78±24 
HB(%) 
 
12.52±36 12.50±71 12.57±33 12.58±47 
T.WBC(×10
6 
/ml) 
11350±242.
89 
11316±462.24 11316±716.70 11312±568.03 
 
PCV  
 
37.57±1.07 37.50±2.13 37.70±96 37.81±1.53 
MCV 91.33±2.42 91.33±1.75 91.83±.75 90.33±4.17 
 
MCH 32.17±2.48 32.33±3.07 30.67±1.75 32.50±1.37 
 
MCHC 35.50±1.87 35.50±2.88 36.50±4.76 33.33±2.50 
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The mean value of T.WBC control and treated groups of wistar albino rats exposed to Inji 
Dravagam in Repeated Oral 90 Days Toxicity study. 
 
 
The mean value of PLATELET control and treated groups of wistar albino rats 
exposed to Inji Dravagam in Repeated Oral 90 Days Toxicity study. 
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The mean value of PCV control and treated groups of wistar albino rats exposed to Inji 
Dravagam in Repeated Oral 90 Days Toxicity study. 
 
 
The mean value of MCV, MCH and MCHC control and treated groups of wistar albino rats 
exposed to Inji Dravagam in Repeated Oral 90 Days Toxicity study. 
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Table: 19 Effect of treatment with Inji Dravagam on biochemical parameters 
Parameter 
 
Control  1ml/kg 5ml/kg 10ml/kg 
GLUCOSE(mg/dl) 117.83±20.29 128.33±13.57 102.83±8.70 89.17±4.62 
UREA(mg/dl) 31.17±5.94 30.50±7.817 26.50±6.89 30.33±4.50 
CREATININE(mg/dl) 0.55±0.18 0.51±.14 0.51±0.13 0.50±0.16 
TOTAL 
BILIRUBIN(mg/dl) 
0.65±0.13 0.85±.0.05 0.81±0.07 0.76±0.15 
SGOT U/L 25.50±4.46 25.00±2.68 23.83±6.99 23.50±5.24 
SGPT U/L 25.00±4.29 27.67±3.07 27.67±5.57 23.00±7.64 
ALP U/L 83.83±9.32 87.50±10.87 90.67±7.03 105.00±5.44 
TOTAL 
CHOLESTEROL(mg/dl) 
107.83±9.32 114.17±7.38 120.33±4.88 112.50±11.53 
TGL (mg/dl) 138.67±6.37 135.50±6.65 139.00±9.83 134.00±6.81 
HDL (mg/dl) 38.38±2.16 46.17±3.76 41.17±2.04 41.33±6.05 
LDL (mg/dl) 41.83±9.66 40.83±8.93 51.33±5.78 44.17±16.01 
VLDL(mg/dl) 27.73±1.27 27.10±1.33 27.80±1.96 26.63±1.60 
 
NS- Not Significant, ** (p > 0.01), * (p >0.05), n = 10 values are mean ± S.D (One way 
ANOVA followed by Dunnett’s test) 
 
The mean value of GLUCOSE control and treated groups of wistar albino rats exposed to 
Inji Dravagam in Repeated Oral 90 Days Toxicity study. 
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The mean value of UREA control and treated groups of wistar albino rats exposed to Inji 
Dravagam in Repeated Oral 90 Days Toxicity study. 
 
 
 
The mean value of CREATININE control and treated groups of wistar albino rats exposed to 
Inji Dravagam in Repeated Oral 90 Days Toxicity study. 
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The mean value of SGOT, SGPT, ALP, of control and treated groups of wistar albino rats 
exposed to Inji Dravagam  in Repeated Oral 90 Days Toxicity study. 
 
The mean value of TOTAL CHOLESTEROL, TGL, HDL, LDL, VLDL, of control and 
treated groups of wistar albino rats exposed to Inji Dravagam  in Repeated Oral 90 Days 
Toxicity study. 
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HISTOPATHOLOGICAL OF CONTROL GROUP ANIMALS 
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HISTOPATHOLOGICAL OF CONTROL GROUP ANIMALS                                          
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HISTOPATHOLOGY OF HIGH DOSE GROUP ANIMAL 
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Spleen  
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Methodology 
All the vital organs obtained were immersed in 10% formalin for 24  h-48h for 
histopathological examination. After standard processing, the cut tissue was embedded in 
paraffin (Leica TP1020 tissue processor) and cut into 5  μm thick sections in a rotary 
microtome (Leica RM2255 - Fully Automated Rotary Microtome). The sections were 
stained with haematoxylin-eosin (Merck). Histological measurement and photographs 
were taken with Olympus CX31, Trinocular Biological Microscope (magnification 10x & 
40 x). 
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Pathologist report 
Kidney 
 Appearance of Podocytes and parietal epithelium in the glomeruli appears normal 
in 3 CM , where as derangement in the cytoarchitecture of parietal epithelium was 
observed in 3HM 
 Proximal and distal convoluted tubule appears normal 
 No signs of lesion or inflammation were observed 
 No signs of cellular necrosis  
Heart 
 Cardiac muscle appears continuous with intact nucleus 
 Myocardial tissue appears normal with orderly striated heart muscle fibers and a 
clear nuclear and muscle bands. 
Liver 
 Marginal infiltration of inflammatory cells were observed in sample belongs to 
3HM on periportal region of liver section 
 Hepatocellular architecture was normal with no signs of necrosis 
Spleen  
 Appearance of central artery and marginal sinus are normal  
 No abnormalities found in lymph node of both the samples 
Stomach 
 Light microscopic observation of both the sample reveals normal histology of rat 
gastric wall composed of mucosa, muscularismucosa, submucosa, 
muscularispropiria and adventitia.  
 No signs of ulceration were observed 
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Interpretation of Sub-chronic toxicity of Inji dravagam 
            All animals from control and all the treated dose groups survived throughout the 
dosing period of 28 days for sub chronic toxicity study. There was significant change in 
the body weight for the control and treatment group throughout the dosing period of 90 
days. 
Hematogological and biochemical parameters of wistar albino rats exposed to Inji 
dravagam have no significant changes when compared to control group. 
Intrepretation of histopathology: 
    The vital organs such as liver, heart, kidneys, stomach and brain were compared with 
the control group and did not reveal any abnormal macroscopic changes. Cross 
pathological investigation was carried out and histopathology of vital organ reveled 
normal histological appearance when compared with the control. 
 
8. PHARMACOLOGY ACTION: 
Table: 20 Effect of Inji Dravagam on Volume of gastric juice 
Group 
No. 
Body wt. gms Treatment Vol. of gastric 
Juice 
I 181.3±1.51 Control (distilled water 
2ml/kg) 
4.7±0.0 
 
II 182.1±2.04 Negative control(Aspirin 
500mg/kg) 
5.48±0.20 
II  181.5±0.84 Standard drug Ranitidine  
(20 mg/kg) 
1.8±0.28** 
III 181.8±1.60 Inji Dravagam (1ml/kg) 4.0±0.0* 
IV 181.3±1.63 Inji Dravagam (2ml/kg) 3.16±0.48** 
 
Effects are statistically significant *P<0.05;**p<0.01 (in comparison with Standard)  
Values are expressed in terms of mean ± SEM of 6 rats (ANOVA) 
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Table: 21 Effect of  Inji Dravagam on PHin Aspirin induced ulcer model 
 
Group No. Body wt. gms             Treatment PH 
I 181.3±1.51 Control (distilled water 2ml/kg) 2.16±0.75 
II 182.1±2.04 Negative control(Aspirin 500mg/kg) 1.8±0.41 
II  181.5±0.84 Standard drug(Ranitidine) 5.16±0.98** 
III 181.8±1.60 Inji Dravagam (1ml/kg) 3.16±0.41* 
IV 181.3±1.63 Inji Dravagam (2ml/kg) 4.0±0.00** 
 
Effects are statistically significant *P<0.05;**p<0.01 (in comparison with Standard)  
Values are expressed in terms of mean ± SEM of 6 rats (ANOVA) 
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Table: 22 Effect of Inji Dravagam  on Free Acidity and Total Acid 
Group 
No. 
Body wt. 
gms 
             Treatment Free acidity Total acidity 
I 181.3±1.5 Control (distilled water 
2ml/kg) 
21.53 ± 0.62 40.02 ± 1.23 
II 182.1±2.0 Negative control(Aspirin 
500mg/kg) 
24.33 ± 1.20 49.05±0.70 
III 181.5±0.84 Standard drug (Ranitidine) 16.11±0.20** 25.63±1.8** 
III 181.83±1.6 Inji Dravagam (1ml/kg) 16.91±0.38* 27.08±1.06* 
IV 181.3±1.63 Inji Dravagam (2ml/kg) 16.03±0.21** 27.00±0.57** 
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Table: 23 Effect of Inji Dravagam on Ulcer index and Percentage of ulcer protection 
Group 
No. 
Body wt. 
gms 
         Treatment Ulcer Index Percentage of 
ulcer protection 
I 181.3±1.5 Control (distilled water 
2ml/kg) 
5.43 ±0.16 
 
       ----- 
II 182.1±2.0 Negative control 6.8±0.58             23.1 
II 181.5±0.84 Standard 
drug(Ranitidine) 
1.48 ±0.35       84.03** 
III 181.83±1.6 Inji Dravagam(1ml/kg) 2.54 ±0.11            63.23 
IV 181.3±1.63 Inji Dravagam(2ml/kg) 1.66±0.15  79.2* 
 
Values are expressed in terms of mean ± SEM of 6 rats (ANOVA) 
Percentage protection = (Control mean ulcer index – Test mean ulcer index)/Control mean 
ulcer index ×100  
Effects are Statistically significant *P<0.05;**p<0.01 (in comparison with Standard) 
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Open excised stomach in Aspirin induced gastric lesions model: 
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a: Inhibition in gastric lesions at control 
b. Gastric lesions induced by Aspirin (500mg/kg)  
c: Absence of gastric lesions in Ranitidine 
d: Fraction inhibition of  gastric lesions at Inji Dravagam (1ml/kg) 
e:fractional inhibition of gastric lesions at  Inji Dravagam (2ml/kg) 
 
Histopathological Examination of Open Excised Stomach in Aspirin Induced Ulcer 
Method: 
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a: Inhibition in gastric lesions at control 
b. Gastric lesions induced by Aspirin (500mg/kg)  
c: Absence of gastric lesions in Ranitidine 
d. Fraction inhibition of gastric lesions at Inji Dravagam 
 
Results of Anti- ulcer (Hyperacidity) activity of Inji Dravagam (ID) in wistar albino 
rats 
 
Gastric volume 
 The gastric volume was increased in aspirin induced group when compared to 
control group. Administration of ID and ranitidine showed a significant (p<0.01) decrease 
in gastric volume level, when compared to negative control. 
pH. 
 The pH level was decreased (p<0.01) in the aspirin induced method, when 
compared to control group. Administration of ID and ranitidine showed a significant 
(p<0.01) increase in pH level, when compared to negative group animals. Results were 
showing Table 21. 
 
Free and total acidity 
 The free acidity (mEq/l/100g) was increased (p<0.01) in the aspirin induced 
animals, when compared to control group. Administration of ID and ranitidine showed a 
significant (p<0.01) decrease in free acidity, when compared to negative control. 
 Total acidity (mEq/l/100g) was increased (p<0.01) in aspirin induced model, when 
compared to control group. Administration of ID and ranitidine showed a significant 
(p<0.01) decrease in total acidity, when compared to negative control. 
 
Conclusion 
Inji Dravagam exhibited anti ulcer activity in aspirin induced  ulcer model for 
screening anti ulcer drugs. The percentage of inhibition of ulcer was 84.03%, 63.23%, 
79.2% produced by the treatment of standard drug Ranitidine, InjiDravagam (ID) at the 
dose level of 1ml/kg and 2ml/kg respectively. In case of vehicle control, aspirin induced 
rats showed increase in acid secretion, which in turn caused increase in gastric volume, 
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low pH, increased free and total acidity resulting in increase of ulcer index. 
  Inji Dravagam (ID) when administered at dose level of ( 1ml/kg and 2ml/kg) 
produced a  reduction in the gastric fluid volume, free acidity, total acidity and ulcer 
index significantly in comparison with control group.  
  
 Hence, based on the results, it can be concluded that the Inji Dravagam, 
significantly p<0.05 and p<0.01,decreased the ulceration in Aspirin induced  ulcer  model 
in rats which suggest a direct ulcer protective effect on the gastric mucosa at the dose 
level of 1ml/kg and 2ml/kg respectively. The result was represented in table 23. 
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Table :24 The results of anti- inflammatory activity by Cotton pellet granuloma method of 
Inji Dravagam 
 
Groups Treatment Mean wet 
weight of 
pellet(mg) 
Percentage 
inhibition 
Mean dry 
weight of 
pellet(mg) 
Percentage 
inhibition 
I Vehicle control 182.2 0 40.8 0 
II Dexamethasone(0.5mg/kg) 90.4 50.3 20.6 49.50 
III InjiDravagam(1ml/kg) 160.4* 13.06 33.6 17.64 
IV InjiDravagam(2ml/kg) 158.4* 11.96 28.3 30.63 
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RESULTS  
The results indicate that Inji dravagam at the dose level of 1ml/kg and 2ml/kg 
produced a decrease in wet granuloma weight 160.4 (11.96% inhibition) and 158.4 
(13.06% inhibition) respectively when compared to control. Similarly there was a 
significant decrease in dry granuloma weight 33.6(17.64% inhibition) and 28.3(30.68% 
inhibition) respectively compared to control. Among the two doses 2 ml/kg showed 
slightly lower reduced weight of granuloma than standard drug which was showed in table 
24. Thus it was concluded that administration of Inji Dravagam at the dose of 2 ml/kg 
exhibited significant (p<0.05) anti-inflammatory activity in Cotton pellet granuloma 
model of inflammation in rats. 
 
 
 
 
 
 
 
0
10
20
30
40
50
Percentage inhibition
Percentage inhibition
100 
 
Table : 25 Analgesic activity of Inji Dravagam  by eddys hot plate method. 
Groups Treament 
 
                                           Reaction time in min 
0min 30min 60min 90min 120min 150min 
I Control 2.08±0.07 2.25±0.10 2.21±0.11 2.18±0.13 2.23±0.10 2.15±0.08 
II Pentazocine 
(5mg/kg) 
2.09±0.04 4.13±0.07 5.11±0.07 7.08±0.13** 8.12±0.10** 12.08±0.07** 
III ID (1ml/kg) 2.16±0.05 3.15±0.08 4.11±0.06 5.08±0.08 7.16±0.13 8.10±0.07* 
IV ID(2ml/kg). 2.09±0.04 4.09±0.04 5.20±0.08 7.16±0.13** 8.12±0.10** 10.18±0.08** 
 
 
n=6 ,values are expressed as mean±SEM  P<0.05 when compared with control. 
Analgesic activity of Inji Dravagam by eddy’s hot plate method. 
The results were analyzed by ANOVA followed by Dunnet's test (p-value <0.05 was taken 
as significant). 
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Analgesic activity of Inji dravagam in swiss albino mice 
 Analgesic activity was carried out by Eddy’s Hot plate method. Analgesic effect 
lasted for a period of 120 min was found to be possess significant (p<0.01) analgesic 
activity at the dose level of 2ml/kg by increase in reaction time (Increase threshold 
potential of pain). Inji Dravagam 1ml/kg showed moderate activity when compared to 
standard drug pentazocine, whereas Inji Dravagam at 2ml/kg showed results more similar 
to that of pentazocine (5 mg/kg). From these results it is obvious that Inji Dravagam has 
significant analgesic activity 
                                               
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
DISCUSSION 
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DISCUSSION 
 
 The drug Inji dravagam was selected to study the anti-ulcer, Anti-inflammatory 
and Analgesic activity. The trial drug was selected from “yaakopu vaithiya chinthamani”  
 The preclinical study substantiated the literary evidence of Inji dravagam in the 
management of Gastrointestinal disorders. 
  
Bio-chemical analysis: 
 Biochemical analysis of the drug Inji  dravagam reveals that the presence of 
Chloride, Calcium , Ammonium and alkaloids. 
 
Toxicological studies: 
 This study reveals that no significant toxic effect of the  drug Inji dravagam upto 
the higher dose level 10ml/kg in acute oral toxicity and also  sub acute toxicity and sub 
chronic toxicity has no toxic effects from the results. Therefore the drug Inji dravagam  
can be classified under the category of drug with non-toxic. 
 
Pharmacological studies: 
 
In the Pharmacological study the experimental data showed that Inji dravagam has 
Anti-ulcer,  Anti-inflammatory  and Analgesic activity and the results are as follows, 
 
Anti-ulcer  
             Inji Dravagam  was found to possess remarkable ulcer protective properties and 
almost exhibited similar effects as that of ranitidine. Hence, based on the results, it can be 
concluded that the Inji Dravagam, significantly decreased the ulceration in Aspirin 
induced gastric ulcer in rats which suggest a direct ulcer protective effect on the gastric 
mucosa. 
 
 activity when compared to standard drug pentazocine, whereas Inji Dravagam 
showed results more similar to that of pentazocine (5 mg/kg). From these results it is 
obvious that Inji Dravagam has significant analgesic activity. 
Anti-inflammatory 
               Inji dravagam exhibited significant anti-inflammatory activity when compare to 
the control 
  
 
 
 
SUMMARY 
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SUMMARY 
 
 
 
 The literary evidence of the drug Inji Dravagam strongly support that it possesses 
anti-ulcer activity, Anti-inflammatory activity and analgesic activity for that 
purpose it has been selected for this study.   
 
 The qualitative chemical analysis was done at Biochemistry lab, NIS. chemical 
analysis of the drug Inji Dravagam reveals that the presence of calcium,, Chloride, 
ammonium and Alkaloid. 
 Preclinical evaluation (acute, sub-acute and sub-chronic toxicity study) of the drug 
was carried out as per OECD guideline acute, and Sub-acute was carried out  in kk 
coll of pharmacy and sub chronic toxicity study were carried out in  
pharmacological lab and animal house, NIS, Chennai. This study reveals no 
significant toxic effect of the Inji Dravagam upto the higher dose level 10ml/kg 
used in this study. 
 
 Pharmacological study (Anti-ulcer activity, Anti-inflammatory activity and 
analgesic activity) of the drug was carried out as per OECD guideline in KK 
College of Pharmacy Gerubambakkam. In the pharmacological studies, the drug 
Inji Dravagam exhibits significant Anti-ulcer, Anti- inflammatory activity and 
analgesic. 
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CONCLUSION 
 
From the literature evidence, Physico chemical analysis, Bio chemical analysis, 
Toxicological evaluation and Pharmacological studies, the drug Inji Drvagam has Anti-
ulcer, anti-inflammatory and analgesic activity. It is concluded that the drug Inji  
Dravagam can be used in the management of Gunmam (peptic ulcer) and the related 
Gastro intestinal disorder. 
 
 
  
 
 
 
BIBLIOGRAPHY 
105 
 
BIBILIOGRAPHY 
1.  S.P.Ramachandhiran, yaakopu vaithiya chinthamani-700 Third edition-1992, published by 
by Indian medicine and homeopathy,   
2. Samuvel,  maarunthu sei iyalum kalaium, first edition, published by Dr.A.Sundarajan. 
3.  sarakku suthi muraigal, published by Indian medicine and homeopathy- 2008 
4. S.murugesamuthaliyar, Gunapadam mooligai vaguppu, ninth edition, published by Indian 
medicine and homeopathy, volume -1. 
5. Shanmugavel, noigalukku Siddha parigarum, fourth edition, published by Indian medicine 
and homeopathy, volume -1. 
6. [7].Kannusamipillai, seegecharathina thepam, first edition, published by by Indian 
medicine and homeopathy. 
8. vaithiya sindhamani, first edition, published by Indian medicine and homeopathy page no 
159.  
9. S.P.Ramachandhiran, yaakopu vaithiya chinthamani-700 Third edition-1992, published by 
by Indian medicine and homeopathy,   
10.P.S.Kuppusamy, annupogavaithiya brammaragasiyam, second edition, published by by 
Indian medicine and homeopathy,  
11. V.R.Madhavan, Agathiar vaithiyakaviyam1500, published by by Indian medicine and 
homeopathy,  
12. Dr.J.Ramachandran, Herbs of Siddha medicine, published by Jayanthi Raamachandran, 
volume I &II, first edition: January, 2008 
13. MDidea Extracts professional www.mdiea.com sep 28
th
 2015 
14. Gaurav Kumar, L. Karthik, K. V. Bhaskara Rao, Gaurav Kumar et al. / Journal of 
Pharmacy Research 2011, 
15. Dr.k.m. Nandkarni, Indian metriya medica, volume-1, published by ramadas bhatkal  
16. A. Anosike, Onyechi Obidoa, African Journal of Biochemistry Research Vol.3 (12),  
December, 2009, ISSN 1996-0778 © 2007, www.academicjournals.org/ajbr 
17. Rajesh Kumar Mishra, international  journal of  pharmaceutical and chemical  sciences. 
18. A. Anosike, African Journal of Biochemistry Research Vol.3 (12), pp. 379-384, 
December, 2009 online at http://www.academicjournals.org/ajbr 
106 
 
 
19.A.K.Gupta, qualitative standards of Indian medicinal plant volume-3 published by Indian 
council of medical research V.Ramalingamswami  
20. Nagalakshmi, S.; Shankaracharya,  Journal of Food Science and Technology (Mysore) 
2000 Vol. 37 No. 3 INSS NO-0022-1155  
21.Mohammad Hossein Boskabady, BioMed Research International Volume 2014 (2014), 
Article ID 569087, http://dx.doi.org/10.1155/2014/569087 
22. S. N. Dwivedi, R. P. Mishra and Sangeeta Alava international journal of  pharmacy & life 
sciences, ISSN: 0976-7126,  
24. BabyChauhan, American journal of pharmetech research 2012, ISSN 2249-
3387,www.ajptr.com. 
(chemical)Ranjan bairwa, Pharmacognosy Review, 2012, Volume : 6,  Issue : 11, 
25.Saleh Alqasoumi, African Journal of Pharmacy and Pharmacology Vol. 5(5), pp. 572-576, 
May 2011 online http://www.academicjournals.org/ajpp 
26.The Siddha formulory of india, part-2, first edition,   
27. The Siddha pharmacopoeia of india, part-1 voll-2 first edition. 
28.D.R Lohar; Protocol for Testing; Department of AYUSH, Ministry of Health & Family 
Welfare, Pharmacopoeial Laboratory For Indian Medicines Publication, Ghaziabad,  
29.OECD. Guidelines for the Testing of Chemicals / Section 4: Health Effects Test No. 423: 
Acute Oral toxicity - Acute Toxic Class Method. Organization for Economic Cooperation 
and Development, Paris, France; 2002 
30.OECD. Repeated dose oral toxicity test method. In: OECD Guidelines for testing of 
chemicals, No. 407. Organization for Economic Cooperation and Development, Paris, 
France; 2008 
31.Organization of Economic Co-operation and Development (OECD) The OECD Guideline 
for Testing of Chemicals: 408 Subchronic Oral Toxicity-Rodent: 90-Day Study. Paris, France: 
OECD; 1998. 
 
  
 
 
 
ANNEXURE 
 
 
 
           
 






  
 
 
 
ACKNOWLEDGEMENT 
  
ACKNOWLEDGEMENT 
 
 This dissertation is one of the milestones in the journey of Siddha drug reaserch. It is 
the key program in acquiring my MD(S) degree. Thus I came across this task which 
kept on completed with the support and encouragement of numerous people. So I take 
great pleasure in thanking all the people who made this dissertation study a valuable 
and successful one, which I owe to treasure it. 
 
 I  feel  enormous  wonder  and  colossal  gratitude  in  my heart  of  hearts  to  GOD 
and  SIDDHARS  Almighty for making this dissertation have its present form. 
 
 I express my sincere thanks to the Vice-Chancellor, The Tamilnadu Dr.MGR 
medical University, chennai-32. 
 
 I express my profound sense of gratitude to Prof. Dr.V.Banumathi M.D(s), Director, 
National Institute of Siddha, Chennai-47. 
 
  I take this opportunity to express my profound gratitude and deep regards to my 
guide & HOD Prof.Dr.M.Rajasekaran M.D(S) National Institute of Siddha, 
Chennai-47, for his excellent guidance, monitoring and constant encouragement and 
guidance given by him time to time throughout the course of this dissertation. 
 
 I express my sincere thanks to Dr.P.Kumar  M.D(s), Associate Prof. Department of 
Gunapadam, NIS.Chennai-47, for his hopeful support and encouragement of my 
whole study. 
 
 I express my sincere thanks to Dr.S.Visweswaran M.D(s), Lecturer, Department of 
Gunapadam, NIS, Chennai-47, for his suggestions, hopeful support and 
encouragement of  my  whole study. 
 
 I express my sincere thanks to Dr.S.Sivakkumar M.D(s), Lecturer, Department of 
Gunapadam, NIS, chennai-47 for his suggestions, hopeful support and encouragement 
of  my whole study. 
 
 I express my sincere thanks to Dr.A.Mariappan M.D(s), Lecturer, Department,  of 
Gunapadam NIS,Chennai-47, for his suggestions, hopeful support and encouragement 
of my whole study. 
 
 I express my sincere thanks to Dr.V.Suba M.Pharm, P.hD., Assistant Professor in 
Pharmacology, NIS, Chennai-47, for her suggestions in the pharmacological study. 
 
 I express my grateful thanks to Dr..J.Rani B.V.sc, veterinarian,(Late) NIS, for her 
healthy support  to me and my test animals throughout my studies   
 
 I express my sincere thanks to Chairman and Members of Institutional Animal 
Ethical Committee (IAEC), National Institute of Siddha, Chennai-47, for their 
valuable guidance. 
 
 I express my sincere thanks to Dr.D.Aravind M.D(s), M.Sc., Assistant Professor, 
Medicinal Botany, NIS, chennai-47. 
 
 I express my grateful thanks to Dr.Senthil kumari.,M.Pharm Ph.D, KK college of 
pharmacy, Gerugambakkam, Chennai-97, for his assistance in the pharmacological 
study. 
 
 I express my sincere thanks to Mr.M.Subramanian M.Sc., (statistics) Senior 
Research Officer, National Institute of Siddha, Chennai-47. 
 
 I express my gratefulness to All My Colleagues and My friends for lending their 
helping hands whenever needed during the course of the study.  
 
 Last but not least, I would like to pay high regards to all my family members,                  
my Father Mr.I.Selvaraj M.A B.P.Ed and my mother Mrs.S.Shanthi for their 
sincere encouragement throughout my research work and lifting me uphill this  phase 
of life. I owe everything to them. Besides this, several people have knowingly and 
unknowingly helped me in the successful completion of this project. 
  
